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S U M M A R Y
motivation Disease progression in cancer can vary substantially
between patients. Yet, patients often receive the same treatment.
Recently, there has been much work on predicting disease progres-
sion and patient outcome variables from gene expression in order
to personalize treatment options. A widely used approach is high-
throughput experiments that aim to explore predictive signature genes
which would provide identification of clinical outcome of diseases.
Microarray data analysis helps to reveal underlying biological mech-
anisms of tumor progression, metastasis, and drug-resistance in can-
cer studies. Despite first diagnostic kits in the market, there are open
problems such as the choice of random gene signatures or noisy ex-
pression data. The experimental or computational noise in data and
limited tissue samples collected from patients might furthermore re-
duce the predictive power and biological interpretability of such sig-
nature genes. Nevertheless, signature genes predicted by different
studies generally represent poor similarity; even for the same type of
cancer.
Integration of network information with gene expression data could
provide more efficient signatures for outcome prediction in cancer
studies. One approach to deal with these problems employs gene-
gene relationships and ranks genes using the random surfer model
of Google’s PageRank algorithm. Unfortunately, the majority of pub-
lished network-based approaches solely tested their methods on a
small amount of datasets, questioning the general applicability of
network-based methods for outcome prediction.
methods In this thesis, I provide a comprehensive and systemat-
ically evaluation of a network-based outcome prediction approach –
NetRank - a PageRank derivative – applied on several types of gene
expression cancer data and four different types of networks. The al-
gorithm identifies a signature gene set for a specific cancer type by
incorporating gene network information with given expression data.
To assess the performance of NetRank, I created a benchmark data-
set collection comprising 25 cancer outcome prediction datasets from
literature and one in-house dataset.
results NetRank performs significantly better than classical meth-
ods such as foldchange or t-test as it improves the prediction perfor-
mance in average for 7%. Besides, we are approaching the accuracy
level of the authors’ signatures by applying a relatively unbiased but
fully automated process for biomarker discovery. Despite an order of
iii
magnitude difference in network size, a regulatory, a protein-protein
interaction and two predicted networks perform equally well.
Signatures as published by the authors and the signatures gener-
ated with classical methods do not overlap – not even for the same
cancer type – whereas the network-based signatures strongly over-
lap. I analyze and discuss these overlapping genes in terms of the
Hallmarks of cancer and in particular single out six transcription fac-
tors and seven proteins and discuss their specific role in cancer pro-
gression. Furthermore several tests are conducted for the identifica-
tion of a Universal Cancer Signature. No Universal Cancer Signature
could be identified so far, but a cancer-specific combination of gen-
eral master regulators with specific cancer genes could be discovered
that achieves the best results for all cancer types.
As NetRank offers a great value for cancer outcome prediction, first
steps for a secure usage of NetRank in a public cloud are described.
conclusion Experimental evaluation of network-based methods
on a gene expression benchmark dataset suggests that these meth-
ods are especially suited for outcome prediction as they overcome
the problems of random gene signatures and noisy expression data.
Through the combination of network information with gene expres-
sion data, network-based methods identify highly similar signatures
over all cancer types, in contrast to classical methods that fail to iden-
tify highly common gene sets across the same cancer types.
In general allows the integration of additional information in gene
expression analysis the identification of more reliable, accurate and
reproducible biomarkers and provides a deeper understanding of
processes occurring in cancer development and progression.
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1 O P E N P R O B L E M S
open problem 1: does network information
improve cancer outcome prediction?
motivation In the last decade microarrays developed to be a pow-
erful tool to predict the outcome of patients in several diseases. In
contrast to standard DNA-based assays that mainly focuses on sin-
gle genes with rare conditions, microarray based methods are perfect
for the investigation of diseases underlying complex genetic causes.
Many recent microarray studies have been accepted by the Food and
Drug Administration (FDA) and are nowadays included in clinical
routines. These studies cover a wide range of malignant and chronic
diseases and improve the live span and quality of many patients.
However, there is an even bigger number of studies that did not
found acceptance as they did not found their way into clinical usage.
Predictive signatures are often
not consistent
A huge topic in outcome prediction based on large scale microarray
experiments is the transferability of signatures in different datasets,
the applicability in other patients than in the patients of the study.
Generally, predictive gene sets derived from different studies for the
same disease tend to have zero overlap, questioning their biological
relevance.
Low statistical power of
microarrays
The problem lies in the microarray experiment itself. Due to lim-
ited financial support, many studies are based on a limited amount of
patients, which of course cannot reflect all possible disease variations.
In addition differs the gene expression between patients but the dif-
ferences are often subtle and the technical noise introduced during
experiments often extends the biological signal.
Integration of network
information improves cancer
outcome prediction
Network information can help to improve outcome prediction and
reduce noise in microarray experiment. Many recent studies applied
network based methods and successfully improved outcome predic-
tion of already published microarray data [40, 42, 45, 61, 129, 172, 181,
196].
To our knowledge, all published network-based approaches test
their methods solely on a small amount of datasets to indicate their
functionality. In this thesis I will test the general applicability of
network-based outcome prediction on a benchmark dataset covering
a wide range of cancer types. For this purpose I evaluate a network-
based algorithm – NetRank – on 26 gene expression datasets.
1
2 open problems
open problems The following questions are answered in this PhD
thesis:
• Is NetRank able to successfully predict the outcome of several
cancer types?
• How does the NetRank accuracies compare to:
1. random signatures,
2. signatures obtained from classical outcome prediction meth-
ods and
3. the original accuracies as published in the benchmark data-
sets?
• Does network outcome prediction provide consistent improve-
ments across different cancer types?
• Does the size of the signature and patient cohort influence the
results?
• Which types of interactions – physical or regulatory – are best
suited? Are current networks sufficiently large?
• Which parameters influence the prediction results of NetRank?
open problems 3
open problem 2: is there a universal can-
cer signature?
motivation Cancer outcome prediction aims to forecast disease
progression from gene expression data. In the last years, many stud-
ies published predictive signatures that allow refined outcome predic-
tion and thus leading to better treatment options. It has been shown,
that single gene markers are not able to reliably predict cancer out-
come. For that reason a combination of several genes is nowadays
used as predictive signatures for outcome prediction. One success
in this area is the diagnostic assay MammaPrint R⃝, which predicts
metastasis formation in breast cancer based on the expression of 70
genes. The original publication claims that these genes predict the
metastasis probability of a patient with an accuracy of 83% [191],
which was later corrected to 69% [120].
No signature overlap for same
type of cancer
Ein-Dor and co-workers compared the breast cancer progression
signature of MammaPrint R⃝ with another study and found that ”the
overlap between these gene sets is almost zero” and that ”many
equally predictive lists could have been produced” [55]. Venet and
co-workers continued these lines and showed in a systematic analysis
that 60% of predictive signatures are not better than random and that
90% of all random signatures with more than 100 genes would be a
comparably good predictor [188].
Integration of background
knowledge improves cancer
outcome prediction
Network information efficiently helps to improve outcome predic-
tion and reduce noise in microarray experiments. In chapter 4 I eval-
uate a network-based approach on several cancer datasets and the
resulting signatures showed overlapping key genes. This strengthen
the results of another study that found a high correlation between
the predictive genes of two breast cancer datasets and claimed that
predictive signatures would reveal underlying mechanisms of certain
diseases [54].
In the last decade, the several stages of cancer development have
been a focus in biomedical research. Hanahan and Weinberg have
summarized the biological capabilities acquired during the multi-
stage development of human cancers in the Hallmarks of cancer [79].
open problems Several questions arise based on the similarity of
predictive signatures:
• How similar are:
1. signatures published by other authors regarding the same
and different biological questions?
2. NetRank signatures intra and inter cancer types?
• Are overlapping genes in NetRank signatures biological mean-
ingful?
4 open problems
• In which relation are these genes to the Hallmarks of cancer?
• Is it possible to construct a Universal Cancer Signature that
is able to detect any kind of cancer by using the overlapping
genes?
• Do we need individual signatures for cancer outcome predic-
tion?
• But then, how do we improve the overlap between signatures
obtained from different datasets?
2 I N T R O D U C T I O N
2.1 problems in cancer outcome prediction
Cancer remains the second leading cause of death in the United
States, behind heart disease, with an estimated 1.6 million new cases
and 580.000 deaths in 2013 alone [165]. It is a highly complex disease,
which can encompass multiple genomic alterations, including gene
amplifications, epigenetic modifications, point mutations, transloca-
tions, aberrant splicing, deletions, and altered gene expression. These
changes may be somatically acquired or inherited during progression
from a normal to a cancerous cell. In the past decade, it has been dis-
covered how these genomic perturbations drive cancer cell survival
by altering the mechanism for apoptosis, cell cycle control, DNA re-
pair, differentiation, and metabolism. By improving the understand-
ing of these molecular mechanisms, scientists have gained greater
insight into the initiation of cancer, its progression, and its sensitivity
to therapeutics.
2.1.1 Goal of cancer outcome prediction
Outcome prediction tries to define the future state of a patient based
on its current disease state. The main goal of cancer outcome predic-
tion is to improve the diagnosis and the treatment of cancer through
more accurate disease classification and patient stratification. Outcome-
based cancer research spans from discovery research to validation
and into clinical utility including:
1. Identification of cancer biomarkers and therapeutic targets,
2. Elucidation of the mechanisms of cancer pathways,
3. Validation of therapeutic targets and cancer biomarkers,
4. Clinical classification and stratification.
2.1.2 Cancer staging - the standard way of outcome prediction
Staging describes the severity of a person’s cancer based on the size
and/or extent of the primary tumor and whether the cancer has
spread in the body. After initial surgery, the state of a tumor is micro-
scopically examined by a pathologist and predictions are made using
different parameters.
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To determine the degree to which a cancer has developed is possi-
ble due to the tumor-node-metastasis (TNM) staging system, which
is a measure of the extent to which the cancer has spread and the
grading of a tumor that is a measure of cell anaplasia in the sampled
tumor and is based on the resemblance of the tumor to the tissue of
origin.
The tumor grading system, described by the American Joint Com-
mission on Cancer guidelines uses numerals I, II, III, and IV to char-
acterize the progression of cancer.
The TNM staging system is the
standard way to access the
prognosis of a patient
The TNM staging system includes several parameters:
1. primary tumor pT: describes the size of the original tumor and
whether it has invaded nearby tissue,
2. regional lymph nodes pN: describes whether nearby (regional)
lymph nodes are involved,
3. distant metastasis M: describes whether distant metastasis oc-
cur,
4. histological grade G: reflects the grade of the cancer cells,
5. residual tumor R: describes the tumor status following treat-
ment and reflects the effects of treatment.
These measures aid medical staff in categorizing the tumor. This
categorization is helpful in treatment planning and for assessing the
prognosis of a patient. They furthermore assist in the evaluation
of the results of treatment and help health care providers and re-
searchers to exchange information about patients.
TNM staging has different
drawbacks
The usability of this system for outcome prediction has been ques-
tioned [28] and it has been shown for several cancer types that the
system is not fine grained enough for effective outcome prediction
[93, 140]. A new system is needed to reliable predict the outcome of
a patient. Gene expression profiling adds a great value to the existing
TNM grading system.
2.1.3 Single gene tumor marker
Besides the TNM grading system, many gene markers are nowadays
in use to guide clinical doctors in making treatment decisions. The
following sections describe some biological markers used in daily rou-
tine as well as the advantages and disadvantages of single gene tumor
marker.
A single tumor marker can be evaluated easily through simple,
noninvasive and cost-effective laboratory tests, yet facilitates earlier
diagnoses and improved treatment outcomes. A single tumor marker
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consists of any product of either the tumor itself or the host in reac-
tion to the tumor’s presence, which distinguishes malignant tissues
from healthy and is measurable in body fluids or tissues.
Usually, tumor markers cover one of the following 5 different types
of proteins and can be either:
1. Oncofetal proteins, such as carcinoembryonic antigen (CEA)
and alpha-fetoprotein (AFP).
2. Hormones, such as calcitonin and human chorionic gonadotropin
(HCG).
3. Organ-specific antigens, such as prostate-specific antigen (PSA).
4. Monoclonal antibody-defined antigens, such as tumor associ-
ated glycoproteins CA 125, CA 19-9, CA 27-29, and CA 15-3.
5. Enzymes, such as prostatic acid phosphatase.
The expression/amount of a protein or single gene tumor marker
can be measured in several ways. As proteins are molecules with a
3D-structure, direct measurement is not easily possible. Proteins are
encoded in the DNA that is transcribed into mRNA, which is later
on translated into the protein. Through measuring the quantity of
mRNA, the expression of a protein can be estimated. A protein is
called up-regulated, when more mRNA is measured than in a com-
parable state and down-regulated vice versa.
Single gene markers in practice
Nowadays, there are many single gene markers in clinical use. Table 1
lists the most used single tumor marker tests nowadays available to
medical doctors and their clearance by the FDA. The following sec-
tion describes some of the single gene marker frequently used in daily
clinical routine.
alpha-fetoprotein Hepatocellular carcinoma (HCC) is one of the
most often occurring cancers worldwide. It develops usually in a
liver suffering already chronic damages as cirrhosis or a viral hepati-
tis infection. Alpha-fetoprotein (AFP) is a major mammalian embryo-
specific and tumor-associated antigen, which progressive elevation
helps to diagnose hepatocellular carcinoma in patients with liver cir-
rhosis [175]. Expression levels of AFP are also influenced by other
diseases like hepatitis C or cirrhosis [75, 143], therefore it cannot not
be used to specifically diagnose HCC. For that reason and because of
having poor sensitivity and specificity the usability of AFP for early-
stage diagnosis is limited. Nevertheless, AFP is a useful marker for
post-treatment control like tumor recurrence [205].
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Table 1: Investigated tumor markers. The last column indicates whether the
marker is approved by the FDA. Information taken from www.cancer.gov
and www.cancer.org
Marker Tumor FDA
Alpha-fetoprotein Liver cancer, germ cell tumours,
ovarian cancer
✓
BCR-ABL Chronic myeloid carcinoma
Beta-2-microglobulin Multiple myeloma, chronic
lymphocytic leukemia, and some
lymphomas
Bladder tumor antigen Bladder cancer ✓
BRAF Cutaneous melanoma, colorectal cancer,
thyroid cancer
CA 15-3 Breast cancer
CA 19-9 Pancreatic cancer, gallbladder cancer,
bile duct cancer, and gastric cancer
CA 27-29 Breast cancer
CA 125 Epithelial ovarian cancer ✓
Calcitocin Medullary thyroid carcinoma
Carcinoembryonic
antigen (CEA)
Colorectal cancer, lung cancer, breast
cancer
✓
Chomogranin A Neuocrine tumors (carcinoid tumor,
neuroblastoma, small cell lung cancer)
Estrogen receptor (ER) Breast cancer ✓
EGFR/HER1 Breast cancer, non-small cell lung
cancer, head and neck cacner, colon,
pancreas
HER2/ERBB2/EGFR2 Breast cancer, gastric cancer, and
esophageal cancer
Human chorionic
gonadotropin (HCG)
Ovarian cancer, germ cell tumor,
choriocarcinoma
IgA/IgG/IgD/IgM Bone marrow cancer
K-Ras Colorectal cancer, lung cancer
Nuclear Mitotic
Apparatus protein
(NMP22)
Bladder cancer ✓
PSA Prostate cancer ✓
Prostatic acid
phosphatase (PAP)
Prostate cancer
S-100 Melanoma
Thyroglobulin Thyroid cancer
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carcinoembryonic antigen The Carcinoembryonic antigen (CEA)
is a protein involved in cell adhesion. It is only present at very low
levels in the blood of healthy adults, but higher levels occur in some
types of cancer. It is specially used in monitoring colorectal cancer
treatment, to identify recurrence as well as to localize cancer spread-
ing [2]. Elevated CEA levels have been also found in other cancer-
ous conditions as gastric carcinoma, pancreatic carcinoma, lung car-
cinoma, breast carcinoma, as well as some non-neoplastic conditions
like ulcerative colitis, pancreatitis, cirrhosis [117].
cancer antigen 125 The carcinoma antigen 125 (CA-125) also
known as mucin 16 is a member of the mucin family glycoprotein.
It is frequently used as tumor marker in ovarian cancer detection.
CA-125 is a powerful tool for detecting ovarian cancer as around 90%
of women with ovarian cancer show elevated levels of CA-125 in their
blood [74]. It is furthermore useful to measure CA-125 levels to ac-
cess the effectiveness of a certain cancer treatment as the disease-free
survival correlates with the decrease of CA-125 in blood [16]. More-
over, Göcze and co-workers showed, that high levels during cancer
treatment are associated with poor survival outcome [70]. Using CA-
125 as a tool for early cancer detection has been controversially dis-
cussed [15, 66]. The major problem is the low sensitivity in early can-
cer stages as well as the lack of specificity in premenopausal women
[131]. These constraints lead to false positives, introducing patients
to unnecessary screening procedures. CA-125 plays a crucial role in
advancing tumorgenesis and tumor proliferation. It helps the tumor
to evade the immune system by suppressing the response to natural
killer cells [142]. Furthermore it allows the formations of metastasis
by promoting cell motility [176] and it reduces the sensitivity of the
tumor cell to cancer treatment [23].
prostate-specific antigen Prostate-specific antigen (PSA) is a
glycoprotein secreted by the epithelias cells of the prostate glands. It
is needed to liquefy the semen allowing sperm to swim freely [12].
The PSA test is approved in the U.S. for annual screening of prostate
cancer for men older than 50 years. It is normally present in the
blood at very low levels, while increased levels of PSA indicate the
presence of prostate cancer. However, prostate cancer can occur with
no elevation of PSA [177], whereas obesity, prostatitis or benign pro-
static hyperplasia (non-cancerous growth of the prostate) can lead to
elevated levels of PSA [13, 126, 187]. This may lead to many false
negatives/positives. For that reason, the usefulness of the PSA test is
controversially discussed 1 .
1 U.S. Preventive Services Task Force http://www.uspreventiveservicestaskforce.
org/prostatecancerscreening/prostatefinalrs.htm
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Advantages of single gene markers
The measurement of tumor associated protein levels in numerous
body fluids or tissues can aid in the monitoring of certain cancers.
Monitoring is defined here as estimating the progression of tumor
growth or as assessing the response of cancer cells to therapy. This
includes the sequential measurement of patients with confirmed di-
agnoses who are undergoing cancer therapy. Increasing tumor
Single gene markers help to
monitor success of therapy
marker concentrations are often indicative for a progressive disease,
whereas decreasing concentrations indicate response to therapy. Con-
stant serum tumor marker levels are widely associated with a sta-
ble disease. Monitoring can also mean serial measurements used to
detect recurrent or residual disease in patients, who are following
primary curative treatment. Continuous elevations in marker concen-
trations are suggestive of residual cancer, while increasing concen-
trations are characteristic of recurring disease. Single gene mark-
Expression levels of single gene
markers are easy to access
ers are also easy to access via non-costly laboratory test as blood
tests, real-time polymerase chain reaction (RT-PCR) and immunohis-
tochemistry.
Drawbacks of single gene markers
Single gene markers come with a main drawback. Most tumor mark-
Single gene marker show often
high levels in non-cancerous
states
ers are expressed in normal as well as cancer cells and often non-
cancerous diseases lead to higher levels of certain tumor markers as
well. Furthermore, not all cancer types express the tumor marker in a
stable amount. It has been found that some patients show no expres-
sion, whereas elevated levels have been measured in healthy persons.
Due to these reasons, using single gene markers seldom leads to high
sensitivity and specificity in cancer diagnosis.
Another problem for early-cancer diagnosis is the detection limit
of proteins in blood. Many proteins are expressed in low abundance
in blood, therefore the measurement is difficult. Large amounts of
cancer cells present in the blood are needed to overcome the detection
limits. It is furthermore well accepted that gene expression differs
Heterogenity of expression
in-between but also within
tissues
in-between tissues. But it has been recently shown, that also within
tissues, even in the same organ or tumor, the gene expression differs
and that there might be a lot of heterogeneity. Rodriguez-Gonzalez
and co-workers investigated the heterogeneity in the case of EpCAM,
which is a cell surface molecule extensively used as marker for the
enrichment of epithelial cancer cells in blood. They show that the
expression of EpCAM in breast cancer can be heterogeneous spread
over the same tumor [152].
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2.1.4 Gene expression profiling with high-density oligonucleotide
arrays - the new way for outcome prediction
To overcome the problems of single gene biomarkers, a combination
of several genes can be used. The following section describes a tech-
nique – the high-density oligonucleotide arrays or DNA-Microarrays
– that helps to measure the expression of thousands of genes simulta-
neously.
The assays can measure gene expression from any biological sam-
ple - from tissue as well as body liquids. As a result, the researcher
obtains a gene expression profile of such a sample at a particular time,
in a single experiment. The comparison of such profiles created from
healthy and cancerous tissue, helps researchers to identify proteins
involved in cancer formation and progression as wells as to identify
how cells react to a particular treatment. The usual goal of such a
study is the identification of a set of genes that change their expres-
sion. It is possible with such a set of genes to predict the outcome of
a patient or to understand the behavior of a cell regarding external
stimuli. A gene is called down-regulated if it has a decreased expres-
sion compared to another tissue or disease state whereas it is called
up-regulated with an increased expression.
First experiments
Numerous studies have used gene expression profiling to describe
tumor samples from different tissues and cancer subtypes since its
initial description by Brown’s group. He and his co-workers made
for the first time use of DNA molecules spotted onto glass slides
to measure the expression levels of thousands of mRNAs simultane-
ously [157].
The first complete eukaryotic genome (Saccharomyces cerevisiae) on
a microarray chip was published in 1997 [101]. Over the past decade,
global gene expression profiling has become a standard tool for path-
way and biomarker discovery. In the past 15 years, almost 20.000 peer-
reviewed publications attest to the value of the high-density oligonu-
cleotide array technology in the area of life sciences.
The structure of microarrays
A typical chip for gene expression profiling of the human genome
is the Affymetrix HG-U133 Plus 2.0 Array, which measures most of
the currently 22.000 known human genes. This microarray chip is a
small (a few centimeters on each side) glass or other solid surface on
which millions of immobilized oligonucleotide probes have been syn-
thesized or robotically deposited in a predetermined array, resulting
in a density of approximately 1 million probes per 1.3cm2. A probe
is a particular 25-nucleotide long single-strand DNA, and 11 to 20
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probes typically correspond to one probeset. To achieve the most reli-
ability and avoid errors, one gene or expressed sequence tag (EST) is
represented by one to several probe sets.
The workflow of a microarray experiment
The basic principle behind microarrays is the hybridization between
two DNA strands that have the property of nucleic acid sequences to
specifically pair with each other by forming hydrogen bonds between
complementary nucleotide base pairs. When performing a micro-
array experiment, the mRNA from the sample has to be extracted,
fragmented and copied into complementary DNA (cDNA) or com-
plementary RNA (cRNA). Afterwards each fragment is fluorescently
labeled and incubated to the chip. During incubation, the cDNA or
cRNA fragments will hybridize to their matching counterpart probes
on the microarray surface. After washing, fluorescent molecules are
excited by using a laser and the measurement takes place by count-
ing of the emitted photons. The entire chip will be scanned and the
result is a digital image, where signal intensities for each probe are
measured and a raw intensity for each probe set is assigned. The
results of the experiment are raw measurements of fluorescence in-
tensities.
To ensure that differences in intensities are truly due to differential
expression, not printing, hybridization, or scanning artifacts, prepro-
cessing has to take place. Preprocessing consists of different steps
of background correction, normalization and summarization, which
lead to a final expression value for each probe set.
Several methods for preprocessing have been published in the last
decade. The most popular are MAS5 [3], Model-based Expression
Index (MBEI) [109], Robust Multi-array Average (RMA) [87] and GC
Robust Multi-array Average (GCRMA) [199]. In numerous compar-
isons none of the methods turned out to be generally superior to any
other method [21, 76, 190, 198].
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2.1.5 The role of microarrays in cancer outcome prediction
Cancer is a broad group of diseases in which genetic changes drive
cells to divide and grow uncontrolled [193]. One method in cancer
outcome prediction is the analysis of gene expression with the help
of high-density oligonucleotide arrays. Due to the application of the
microarray technology in medical research, numerous studies were
conducted to shed light on gene expression alterations in cancer cells.
Four different applications can be investigated though comparison of
RNA expression levels:
1. Diagnosis of a Disease - Comparing cancer tissue with healthy
tissue,
2. Prediction of success/failure of treatment - Comparing cancer
cells treated with different reagents,
3. Subtyping different types of cancer - Comparing tissue samples
of the same type of cancer,
4. Prediction of tumor progression - Comparing gene expression
in a patient tissue sample with a clinical parameter.
During diagnosis, genes are identified whose changes in expres-
sion correlate with certain cancer phenotypes. In contrast, for pre-
diction of treatment response, genes and proteins that are involved
in the mode of action of that reagent or cause therapy related side
effects such as resistance, have to be identified. Treatment response
includes a prolonged metastasis-free survival or faster response to
therapy. Subtyping copes with finding genes that represent different
subtypes of cancer. This is important as various subtypes may dif-
fer in the aggressiveness of the cancer along with different spreading
behavior and may end up in different treatment needs. Finally, in
prediction of cancer progression, genes have to be identified whose
expression correlates with a clinical parameter of the patient such as
metastasis.
Once a signature of genes is found for one of these applications,
the medical doctor would execute a lab test measuring expression of
the signature genes for a patient, and use this information for his
decision on how to start/proceed with a therapy.
Gene expression-based applications in clinical use
The following section describes different clinical application used (or
in application to be used) for cancer outcome prediction in a medical
environment. The majority of these tests has been proven successfully
and is nowadays used in the daily clinical routine. All assays are
based on the measurement of gene expression.
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Table 2: Several tests assesseing the outcome of breast cancer are nowadays
available. Table is adapted from [7].
Test Reference No.
Genes
Output
MammaPrint R⃝ van’t Veer et
al. [185]
70 2 Categories of tumors
with different risk to
develop metastasis at
10 years.
Oncotype
DXTM
Paik et al.
[138]
21 Recurrence score: risk
of 10-year distant
recurrence in
ER-positive, lymph
node negative
patients.
Theros-Breast
Cancer Gene
Expression
Ratio Assay R⃝
Ma et al.
[116]
3 HOXB13:IL17R ratio
stratifies ER-positive
breast cancer into low
or high risk for
recurrence and is
predictive of benefit
from endocrine
therapy.
PAM50/Breast
BioClasifierTM
Parker et al.
[141]
55 Continuous risk of
recurrence.
MapQuantTM Sotiriou et al.
[167]
8 Genomic Grade Index
Divides histologically
defined G2 tumors.
Mammostrat R⃝ Ring et al.
[151]
5 Mammostrat risk
score: high, moderate,
or low risk of
recurrence after
tamoxifen treatment.
In the field of breast cancer alone, several tests are available. Ta-
ble 2 shows different breast cancer outcome prediction tests nowa-
days available in clinical routine. The test of MammaPrint R⃝ and On-
cotype DXTM, as well as other non-breast cancer tests are explained
in more detail in the following paragraph.
mammaprint R⃝ MammaPrint R⃝ is a microarray-based test that em-
ploys 70-genes developed by van’t Veer et al. [185] to assess the risk of
metastasis caused from breast cancer. The signature was published
2002 in Nature from the Netherlands Cancer Institute. In this publi-
cation, patients are classified by calculating the correlation coefficient
between a patient’s expression levels of the 70 genes and an average
low risk (good prognosis) expression profile. If the correlation co-
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efficient exceeds 0.4, the patient is classified as having a low risk, if
less, the patient is classified as having a high risk of cancer recurrence.
Two independent validation studies were conducted to assess the per-
formance of the 70-gene signature. The validation by van de Vijver
et al. with 151 patients showed a 10 year survival of 95% for low-risk,
and of 55% for high-risk patients [191]. In an independent European
validation with 302 patients [30], the accuracy for the metastasis-free
survival at 10 years was 88% for low-risk patients, and 71% for high
risk patients. The test was approved by the FDA in 2007 for use in the
United States. The Mindact clinical trial is an international prospec-
tive phase 3 study investigating the clinical utility of the MammaPrint
70-gene expression signature [155]. Until 2011, more than 6600 pa-
tients have joined the clinical trial. One of the main goals of the study
is to prove that low risk patients can safely spare chemotherapy.
oncotype dxTM Oncotype DXTM is a diagnostic test that quantifies
the likelihood of disease recurrence in women with early-stage breast
cancer and assesses the likely benefit from certain types of chemo-
therapy. Oncotype DX uses the expression levels of 21 genes within
a tumor to determine a recurrence score, which lies between 0 and
100. The score represents the likelihood of breast cancer recurrence
within 10 years after initial diagnosis. To retrieve the score formalin-
fixed, paraffin-embedded tissue samples have to be sent to Genomic
Health, where they are analyzed via RT-PCR. Five of the 21 genes
are reference genes used to normalize the expression of the cancer
genes. The remaining 16 genes are associated with cell proliferation,
cellular invasion, HER2 and estrogen activity. Since Oncotype DX
became available in 2004, it has been used by over 19,000 physicians
to help to guide treatment for over 350,000 patients in 70+ countries2.
The MammaPrint and the Oncotype DX test have only one gene in
common.
roche amplichip R⃝cyp450 test The AmpliChip CYP450 Test, de-
veloped by Roche, performs genotyping of two Cytochrome P450
(CYP2D6 and CYP2C19) genes, which play a major role in the metabo-
lism of an estimated 25% of all prescript drugs. It is intended to be
an aid to clinicians in determining therapeutic strategies and treat-
ment doses for therapeutics metabolized by the CYP2D6 or CYP2C19
gene product. The test uses purified genomic DNA extracted from
whole blood. The assay distinguishes 29 known polymorphisms in
the CYP2D6 gene, including gene duplication and gene deletion, as
well as two major polymorphisms in the CYP2C19 gene. In 2004, the
test was approved by the FDA.
2 Information taken from http://www.oncotypedx.com/en-US/Breast/
PatientCaregiver/OncoOverview?sc_lang=en-GB
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pathwork R⃝ diagnostics’ tissue of origin test The Pathwork R⃝
Tissue of Origin, from Affymetrix, is a microarray assay, that mea-
sures the expression pattern of more than 1,500 genes and compares
them to the expression pattern of a panel of 15 malignant tumors.
The data is compared to the following malignant expression pat-
terns: bladder, breast, colorectal, gastric, hepatocellular, kidney, non-
small cell lung, ovarian, pancreatic, prostate, and thyroid carcinomas,
melanoma, testicular germ cell tumor, non-Hodgkins lymphoma, and
soft tissue sarcoma. The company’s Pathwork R⃝Tissue of Origin Test
is the only FDA-cleared, molecular diagnostic test to define the origin
of a tissue. It helps pathologists and oncologists in the diagnosis of
challenging cancer cases such as those that are metastatic or that have
a complex clinical history.
amlprofilerTM molecular diagnostic assay The AMLprofiler,
from Skyline Diagnostic, simplifies the challenging task of recogniz-
ing acute myeloid leukemia subtypes and making individualized
therapy decisions. It is a diagnostic microarray assay that detects
mutations in NPM1 (nucleophosmin) and CEBPA (CCAAT/enhancer
binding protein) and determines expression levels of 2 genes with
prognostic significance in AML (EVI1 and BAALC). The clinical trial
to pursue FDA pre-market approval for the AMLprofiler was unsuc-
cessful due to a lack of participants 3.
Problems of gene expression-based outcome prediction
The successes in the area of gene expression-based identification of
cancer biomarkers are the diagnostic kits MammaPrint R⃝ and Onco-
type DXTM.
MammaPrint predicts metastasis formation in breast cancer from
the expression of 70 genes. It is in the market since 2007 and has
been tested on more than 6600 patients in the meantime. Oncotype
DX – another multigene signature – is based on RT-PCR of 16 cancer-
related genes and 5 reference genes. It is commercially available since
2004 for a similar use; predicting the recurrence of tamoxifen-treated,
node-negative breast cancer [138].
Accuracy of MammaPrint not
reproducible
Despite the success of MammaPrint R⃝, the approach has been criti-
cized. The original paper underlying MammaPrint argued that up to
80% of patients receive unnecessary chemotherapy [185] and showed
a prediction accuracy of 83%, but this was later on corrected to 69%
[120].
Signature overlap between
breast cancer studies not
significant
Ein-Dor et al. compared the 70 genes signature published by van’t
Veer and a different signature of 76 genes by Wang et al. [192]. They
concluded that ’the overlap between these gene sets is almost zero’
and ’many equally predictive lists could have been produced’ [55].
3 http://clinicaltrials.gov/show/NCT01463410
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Recently, Venet et al. continued along these lines and showed in
a systematic analysis that 60% of the analyzed signatures were not Random signature with more
than 100 genes as good as any
constructed signature
better than random and that more than 90% of random signatures
with over 100 genes were significant outcome predictors [188].
Besides the problem of random signatures, the use of microarrays
has been the subject of discussion: Michiels and co-workers showed
in seven large cancer prognosis studies that signatures derived by
microarray data analysis do not achieve prediction accuracies better
than random [120]. Furthermore, DNA microarray technology has ba- DNA microarray technology
exhibit biological limitationssic limitations which include: (1) cross-hybridization between genes
of similar sequence [133, 154]; (2) not all genes are reliably detectable,
especially those with a low expression level [94]; (3) lack of informa-
tion about the exact length and sequence of the mRNAs being ana-
lyzed; and (4) the inability to detect novel transcripts. Moreover, the
comparison of expression levels across different experiments is often
difficult and may require complicated normalization methods.
On the other hand, a large study of over 50 groups came to the
conclusion that technical noise in microarrays is low [161]. Applied
to cancer, Dobbin et al. concluded that biological variation between
tumors exceeds technical variation [51].
Despite the discussion about the reliability of microarray, many
other studies continue using this technology. After the landmark
publication of van’t Veer et al., other publications reported signatures
that also predict the relapse risk of breast tumors [19, 83, 97, 167, 192].
Having such a huge amount of predictive signatures, clinicians need
guidance on usage and interpretation. Galina and co-workers pub-
lished a framework for oncologists to understand and evaluate these
biomarkers in clinical application [67].
2.2 network-based cancer outcome predic-
tion
The last sections introduced microarrays and discussed problems oc-
curring during standard gene expression analysis. Such problems in-
clude only a small similarity between predictive signature and noise
in the gene expression data. The following section gives an overview
over different approaches employing various types of network infor-
mation to overcome the mentioned problems.
2.2.1 The idea of network-based outcome prediction
Both problems, i.e. random signatures and noisy expression data, can
be addressed by data integration [84]. Assuming that the three in-
dependent statements ’A is up-regulated’, ’A regulates B’ and ’B is
up-regulated’ have each an error probability of 10%, then the joint
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statements have only an error probability of 0.1%. Hence, the error
can be reduced by integrating consistent pieces of knowledge. Ideker
and co-workers summarized this general principle and also applied
it to the above breast cancer data combining gene expression with
protein interaction data [42]. This lead to an improvement of 8% com-
pared with the corrected accuracy of van’t Veer [185].
Network-based outcome
prediction improves prediction
accuracy
Other studies followed these lines and show, that network informa-
tion efficiently helps to improve outcome prediction and reduce noise
in microarray experiments [62]. For this purpose, network informa-
tion has been integrated with microarray data in various studies in
the last decade. The basic principle of all network-based analysis is
the usage of functional association networks. Edges in these networks
are based on integration of different sources such as high-throughput
experiments (like yeast-2-hybrid), physical binding extracted from lit-
erature or co-expression networks built from microarray as well as
sequencing experiments. Furthermore, gene annotations from Gene
Ontology [8] or MeSH [153] can be used to build associations between
genes. Although such a network covers only a limited number of real
interactomes, integration of microarray and network data has been
shown to dramatically improve the outcome prediction of diseases.
Network-based outcome
prediction creates consistent
signatures
In addition, the integration of such network information reveals
high overlap between predictive signatures. Dutkowski and co-workers
found a high correlation between the predictive genes of two breast
cancer datasets and claimed that predictive signatures would reveal
underlying mechanisms of certain diseases [54].
Network-based analysis is nowadays not only used in cancer out-
come prediction, but also in different biomedical applications such as
drug repositioning, [200], neurodegenerative disorders [71] and for
the interpretation of genomic variation data [78].
Based on these observations, we hypothesize that network-based
methods are able to substantially improve cancer outcome prediction
through data integration. The results of such methods are overlap-
ping signatures, which reveal more insights into the working mecha-
nism of cancer.
2.2.2 State-of-the-art network-based approaches
Integration of gene expression and network information has been
proven to identify enhanced gene signatures providing better out-
come prediction [62]. For this purpose network information has been
integrated with microarray data in various studies in the last decade.
Table 3 gives an overview of different network-based methods. In
the last years many studies adopted the idea of network-based out-
come analysis, but moved from gene expression data to sequencing
data [4, 5, 48, 68, 69, 103, 105, 184]. Integrating protein-protein inter-
action (e.g. HPRD) seems to be more successful than pathway infor-
mation (e.g. KEGG and GO).
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Table 3: The table gives an overview over different network-based predic-
tion methods: if they use PageRank (PR) or greedy methods for signature
identification; if they use protein-protein interaction (PPI) or Pathway infor-
mation; if they want to obtain predictive subnetworks or single genes and
what type of data they use.
Greedy Type of
Author Net PR Search Marker Data
Akula et al. [5] PPI ✓ ✗ subnetwork sequencing
Davis et al. [48] Pathway ✓ ✗ single gene sequencing
Hai et al. [77] PPI ✓ ✗ single gene expression
Johannes et al. [89] PPI ✓ ✗ single gene expression
Lee et al. [103] Pathway ✓ ✗ single gene sequencing
Nibbe et al. [129] PPI ✓ ✗ single gene expression
Osmani et al. [134] own ✓ ✗ single gene expression
Tarca et al. [174] Pathway ✓ ✗ subnetwork expression
Winter et al. [196] PPI ✓ ✗ single gene expression
Yang et al. [202] Pathway ✓ ✗ single gene expression
Akavia et al. [4] Pathway ✗ ✗ single gene expression,
sequencing
Garcia-Alonso et al. [68] PPI ✗ ✗ subnetwork sequencing
Chen et al. [37] PPI ✗ ✗ single gene expression
Chowdhury et al. [40] PPI ✗ ✗ single gene expression
Chuang et al. [42] PPI ✗ ✓ subnetwork expression
Dao et al. [45] PPI ✗ ✓ subnetwork expression
Dao et al. [46] PPI ✗ ✗ subnetwork expression
Fortney et al. [61] Pathway ✗ ✓ subnetwork expression
Guo et al. [73] PPI ✗ ✗ subnetwork expression
Gilman et al. [69] Pathway ✗ ✓ subnetwork sequencing
Leiserson et al. [105] Pathway ✗ ✓ subnetwork sequencing
Su et al. [172] PPI ✗ ✓ subnetwork expression
Ulitsky et al. [181] PPI ✗ ✗ subnetwork expression
Vandin et al. [184] PPI ✗ ✓ subnetwork sequencing
Recent work by the Ideker lab defines subnetwork activity as the
aggregate expression of genes in a given subnetwork [42]. The score
of each subnetwork is derived from the mutual information between
the subnetwork activity and the outcome variable. The greedy search
algorithm is used to identify subnetworks with discriminative activ-
ities. An extension of this approach aims to infer activity levels of
pathways for disease classification by overlaying gene expression on
pathways and searching discriminative gene sets related to the dis-
ease phenotype [102].
Another approach developed by Chowdhury and Koyutürk consid-
ers binary representation of gene expression data to retrieve subnet-
work markers. The algorithm identifies subnetwork markers that are
composed of genes deregulated in the same direction (either up- or
down-regulated) [40]. This group recently introduced an extension of
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their previous algorithm by creating networks associated with known
genetic marker instead of subnetwork associated with random genes
[41]. Both methods were validated on colon cancer and the authors
were able to predict colon cancer metastasis with high confidence.
A different approach of Ulitsky et al. tries to detect modules that
capture genes which not only show highly similar expression behav-
ior but that also exhibit significant correlation with different clinical
parameters [181]. The extension of this work aims to explore dereg-
ulated pathways enriched with genes representing common regula-
tions for some outcome classes of a disease [85].
Su et al. identifies pathways containing many differentially expressed
and co-expressed genes from protein-protein interaction networks
and greedily combines these paths to obtain subnetwork markers
for using disease phenotype classification [172].
In order to classify disease phenotypes, Dao and coworkers develop
a density-constrained biclustering approach taking into account path-
ways being dysregulated in many, but not necessarily all samples
[45].
Fortney et al. incorporate topological modularity into the expres-
sion for subnetwork score by combining genes with high correlation
to the outcome variable and with a high modularity [61].
By an edge-based simulated annealing algorithm Guo et al. identify
responsive subnetworks for prostate cancer [73].
2.2.3 PageRank-based methods
Page and Brin revolutionized the world of search engines by introduc-
ing the PageRank algorithm [137], which is a way of measuring the
importance of website pages. The basic idea behind PageRank is that
a document should be important if it is highly referenced by other
documents. Moreover, citations from important documents should
have more weight than citations from unimportant documents. As
employed by the Google Internet search engine, the PageRank algo-
rithm uses hyperlink information between documents in the world
wide web to assign a numerical weighting (termed the PageRank) to
each document with the purpose of measuring its relative importance
within the set of all web documents. The PageRank algorithm fur-
ther introduces a constant d representing the probability of randomly
jumping to a document instead of following a hyperlink pointing to
it. The PageRank for a webpage is calculated as the following:
rnj = (1− d) + d
N
i=1
wijr
n−1
i
degi
1 ⩽ j ⩽ N (1)
A link from page i to page j is regarded as a "vote of confidence"
for page j from page i. The algorithm views the web as a directed
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graph G(V ,E), with V being the web pages and E the edges, which
represent the links between pages. This information can be stored
in an adjacency matrix, W ∈ RN×N, where wij = 1 if there is a link
from page i to page j and wij = 0 otherwise. We define degi to be the
degree of the ith page. Suppose we have assigned an initial ranking
r0 ∈ RN. The PageRank algorithm proceeds iteratively, updating the
ranking for the jth page from 1 to N according to the formula. Here
rnj denotes the ranking of page j at the n
th iteration and d ∈ (0, 1)
is a fixed parameter. The damping factor d regulates the influence
of the network on the results. The higher the value of d, the lower
the probability to randomly jumping to a document. Google uses a
damping factor of 0.85
Many studies use PageRank for
cancer classification
Several recent studies have applied the idea of using the PageRank
algorithm for both, classification of cancer tumor data [77, 89, 124,
129, 134, 174, 196, 202] and genome wide association studies [5, 48,
103].
Nibbe et al. apply the PageRank algorithm to identify predictive
subnetworks by identifying cross-talking proteins between seed genes
obtained from other cancer related studies [129]. Hai et al. [77] and
Osmani et al. [134] use the PageRank algorithm to identify character-
istic genes specific for a disease by selecting highest ranked genes on
a regulatory network which is constructed based on pairwise expres-
sion correlations. Another approach aims to explore the effects of
gene expressions on the pathways as they calculate an impact score
of each pathway for the specific disease conditions [174].
GeneRank, a Gene Ontology
based PageRank
Morrison et al. recently introduced a modified version of Page-
Rank, which they called GeneRank [124]. The GeneRank algorithm
is an adaptation of PageRank which uses networks where genes are
connected if they share a Gene Ontology annotation. The authors
adapted the algorithm to work with biological data: Gene Ontol-
ogy annotation and gene expression data. Here, the connections
in the network are no longer hyperlinks but genes are connected if
they share a Gene Ontology annotation. Thus, GeneRank combines
the gene expression data with topological information thus boosting
highly connected genes having low gene expression.
The following sections describe approaches using the idea of Gene-
Rank in detail.
NetRank
NetRank, a PPI network-based
PageRank
The NetRank algorithm is a network-based prediction approach for
identifying marker genes benefiting from gene expression and net-
work data. Instead of Gene Ontology annotations as applied in Gene-
Rank, NetRank employs known transcription factor-target relation-
ships, protein-protein interaction, and gene co-expression to define
three different gene-gene networks. For that purpose, NetRank first
assigns a score for each gene and then the network is used to spread
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Figure 1: The general work-
flow of NetRank. First, the
full dataset is randomly split
into the training and test
set. The test set is put aside
and later used for valida-
tion. Then an additional inner
cross-validation loop is added
to define the best damping
factor for the training set. Af-
terwards, NetRank is run on
the training set using the best
damping factor and the most
different 10 genes are selected.
These genes are used to train
a classifier on the training set,
which is used to predict the
outcome of the remaining test
set patients. The whole pro-
cess is repeated 500 times and
a final accuracy is obtained by
averaging over the 500 runs.
this correlation to its neighbors and beyond. The genes with the high-
est NetRank score are then selected as signature genes. The gen-
eral workflow of NetRank is pictured in Figure 1. The algorithm is
applied in a Monte Carlo cross-validation, which is a relatively un-
biased evaluation strategy. The novelty of the NetRank algorithm is
the dynamic setting of the damping factor d as part of the Monte
Carlo cross-validation workflow. Different values of d ranging from
0 to 1 in steps of 0.1 are used and no information of the test set is
integrated for the choice of an optimal d value. More details on the
NetRank algorithm can be found in chapter 4.
The authors applied the algorithm to predict survival in 30 patients
with pancreatic cancer. They found 7 transcription factors with a
predictive power 0.68 (AUC) in a leave-one-out cross-validation [196].
Furthermore, they validated the prognostic value of the candidate
markers by using immunohistochemistry on an independent set of
412 pancreatic cancer samples.
Reweighted Recursive Feature Elimination (RRFE)
An approach similar to NetRank has been developed by Johannes
et al., which identifies the significant genes from an interaction net-
work to predict breast cancer risk of patients [89]. The algorithm –
called Reweighted Recursive Feature Elimination (RRFE) – identifies
significant genes by stepwise elimination of features [89]. For a sta-
ble accuracy computation 10-fold cross-validation is used. Figure 2
shows the general workflow of the algorithm. First, a PPI network is
created by using data from the Human Protein Reference Database
(HPRD). As a next step, the GeneRank is calculated for each node in
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Figure 2: The workflow of
the Reweighted Recursive
Feature Elimination (RRFE)
approach [89]. First, a PPI
matrix is created using HPRD
data. The gene-expression
dataset is split, such that
90% is used as training set.
The remaining 10% is later
used for evaluation. Then,
foldchange is used as input
for GeneRank to rank the
features. In the next step, a
SVM is trained on all features
and the lowest 10% of the
features is discarded. This
procedure of eliminating
genes is repeated until the
set of surviving features is
empty. Afterwards, the SVM
with the optimal number of
features is selected and tested
on the test set. The whole
process is repeated 10 times.
the network and a SVM with linear kernel is trained on all features/-
genes. For GeneRank, a damping factor d of 0.5 is used, as suggested
in the original GeneRank publication. After the training, a RFE-score
is calculated for each node based on the GeneRank and the impor-
tance of that feature/gene for the SVM. This RFE-score takes into
account both the impact of a particular feature on the weight vector
of the hyperplane and the connectivity of that feature in the under-
lying biological network. After ordering the list of features, 10% of
features with the smallest RFE-score are removed. This procedure of
calculating SVM, re-scoring and feature elimination is repeated until
the set of surviving features is empty. After finishing the elimination
process, the best feature combination has to be selected based on the
leave-one-out error.
Johannes et al. tested their approach on real data from breast can-
cer patients. They predicted relapse events based on gene expression
with an AUC of 0.67, which was superior to all methods they com-
pared with.
They furthermore found a high overlap of resulting features in the
10-fold cross-validation process.
netSAM
Yang and co-workers used the GeneRank algorithm to prioritize net-
work hubs [202]. Their framework can be found in Figure 3. The au-
thors start with extracting differentially expressed genes with a fold-
change larger than 2 and a p− value less than 0.01. Out of these dif-
ferentially expressed genes they infer two types of networks, a ’case’
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Figure 3: The workflow of
netSAM. First, differentially
expressed genes are extracted
from GEO. A differential net-
work is constructed through
comparison of the difference
of the interactions and the
subtraction of a ’case’ from a
’control’ network. Then, dif-
ferential expressed network
hubs are prioritized through
GeneRank. Besides, as-
sociations between differen-
tial genetic interactions and
known pathways are investi-
gated. GO Analysis of Can-
didate Genes from GeneRank
and pathway analyses leads
to the final network-based bio-
marker. The figure is adapted
from [202].
and a ’control’ network, via boosting regression. Afterwards, they
identify differential network hubs via subtraction of the ’case’ from
the ’control’ network. These hubs get prioritized via the GeneRank
algorithm. As a final step, a Gene Ontology analysis is conducted. In
their analysis the damping factor d is set to 0.5, as suggested in the
original GeneRank publication.
The algorithm was validated on synthetic datasets and achieved an
AUC of 0.80. After applying netSAM to two real breast cancer data-
sets from Wang et al. [192] and van de Vijver et al. [191], they showed
that genes selected by netSAM are higher enriched in cancer related
terms than genes found by standard methods (t-test and lasso).
2.2.4 Related Work
In a recent work Cun and Fröhlich applied fourteen published gene
selection methods of which eight are using network information on
six public available breast cancer datasets [44]. They compared the
results with respect to prediction accuracy, signature stability and
biological interpretability. Regarding the prediction accuracy they
did not find a general advantage of network-based methods over
standard analyses methods (e.g. PAM [178] or SAM [180]). Never-
theless, some of the network-based methods revealed significantly
higher gene selection stability. Biomarker signatures developed by
network-based approaches revealed a high enrichment of disease re-
lated genes, KEGG pathways and known drug targets.
Altogether, they showed that some network-based approaches have
significantly higher signature stability, but do not perform better than
classical methods. The question arises if these results supports the
conclusions made in this thesis (see subsection 4.3.6).
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2.3 universal cancer signature
Elevated levels of single gene markers as shown in Table 1 are often
not only found in a single type of cancer. Perkins and co-workers
showed, that e.g. the carbohydrate antigen CA 19-9 does not only
show elevated levels in pancreas cancer but also in other cancer types
as colon, esophageal and hepatic cancers [144]. They also found the
oncofetal protein alpha-fetoprotein differentially expressed in hepato-
cellular carcinoma as well as in gastric, billiary and pancreatic cancers.
This points towards that several cancers share the same mechanism
of survival, tumor growth and invasion.
In the last decade the different stages of cancer development have
been a focus in biomedical research. Hanahan and Weinberg have
summarized the biological capabilities acquired during the multi-
stage development of human cancers in the Hallmarks of cancer [79].
These Hallmarks of cancer represents distinctive biological processes
that are responsible for e.g. tumor growth, invasion and metastatic
dissemination. Imagine a signature that is able to predict general
cancer outcome is existing, this signature should cover most of the
Hallmarks.
The usage of networks for outcome prediction reveals high overlap
between predictive signatures. Shi et al. developed a network-based
signature for colorectal cancer recurrence by integrating several col-
orectal cancer signatures and interaction networks. They highlighted
the dysregulated biological processes in colorectal cancer recurrence
[162]. In addition, Dutkowski and co-workers found a high correla-
tion between the predictive genes of two breast cancer datasets and
claimed that predictive signatures would reveal underlying mecha-
nisms of certain diseases [54].
In contrast, a study compared two studies focusing on breast cancer
progression and compared their signatures [55]. They found, that the
overlap between these gene sets is almost zero and that many equally
predictive lists could have been produced, indicating that no general
cancer signature is existing.
Although these breast cancer signatures are not overlapping, com-
mon effected biological processes are captured, proving the analo-
gous predictive power of the signatures [58].
2.3.1 Network-based analysis revealed overlap of signatures be-
tween different types of cancer
Integration of gene expression and network information revealed
more efficient gene signatures providing better outcome prediction
[40, 42, 45, 61, 129, 172, 181, 196].
A network-based outcome prediction approach – NetRank – is in
this study applied on several types of cancer gene expression data.
NetRank is a PageRank derivative, which assigns a rank score to a
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gene, being a combination of its score and the scores of genes linked
to it. Basically, if a gene is linked to other highly ranked genes, it will
also get a high rank due to the boosting effect of neighboring genes.
Hence, the algorithm provides an integration of the topological infor-
mation (i.e. connectivity and random walk) and microarray data (i.e.
node score) to explore crucial signature genes for the outcome pre-
diction. While systematically evaluating the network-based outcome
prediction on 25 literature derived cancer datasets and one in-house
dataset, we show that fully automated integration of network infor-
mation and gene expression data leads to more accurate outcome pre-
dictions compared to the signatures of previous studies and classical
methods such as t-test and foldchange (see chapter 4). The predicted
signatures for a specific cancer type are more interpretable and re-
producible. Furthermore, signatures predicted by NetRank show a
high similarity even for different types of cancers. Hence, the biolog-
ical mission and prognostic ability of such similar signatures will be
investigated in more detail (chapter 5).
Cancer biomarkers can be classified into three main classes: prog-
nosis, predictive and pharmacodynamics [156]. Prognosis biomarkers
aim to distinguish patients having good or poor prognosis. Predictive
biomarkers determine which drugs would be effective for treatment
of a specific tumor. Pharmacodynamics biomarkers define the op-
timal dosage of a drug for a patient. The signatures predicted in
this study are more adequate for prognosis, since they help to dis-
criminate tumor behavior (e.g. good, poor, aggressive) and to make
decision for treatment.
2.3.2 Is there already a Universal Cancer Signature?
An anti-profile signature was developed in another study, where the
genes show hyper-variability across tumor samples and are selected
as biomarker to discriminate healthy and cancer patients [27]. This
anti-profile identifies colon cancer patients using peripheral blood
samples with an AUC of 0.89. The universal cancer anti-profile can
also distinguish healthy and cancer patients (with different tissues)
with more than AUC of 0.92.
There are two aspects that have to be considered: What are the
key roles of the single genes in the predictive signatures in the cancer
progression? Does a Universal Cancer Signature exists that could
possibly predict prognosis or progression of different cancer types?
3 M E T H O D S
The following section describes methods used for the evaluation of
network-based outcome prediction approaches. The general idea as
well as the algorithmic details of NetRank is explained. The classical
approaches are introduced as well as the formula to calculate accu-
racy and signature similarity. Finally, the detailed workflow for the
benchmark dataset creation is explained.
3.1 netrank algorithm
general idea of netrank A general overview of the idea of Net-
Rank is depicted in Figure 4. First a value representing either the
expression change between the different outcome groups or the corre-
lation of the expression with the outcome variable is overlaid with the
network. Often these values do not represent the biological truth. The
central and highly connected node is only represented by a relatively
small value of 0.4 compared to other less connected nodes. This node
represents an important hub that either physically interacts with or
regulates many different nodes. The small value compared to other
nodes might be due to biological or technical noise happening during
the experiment. After applying NetRank the values are representing
the high biological relevance and highly connected genes tend to have
high scores, when neighboring nodes are highly expressed.
Figure 4: Before NetRank,
the values are not represent-
ing the biological truth as the
central node is represented by
a relatively small value com-
pared to other less connected
nodes. This might be due to
biological or technical noise
happening during the exper-
iment. After applying Net-
Rank the values are represent-
ing the biological relevance
and highly connected genes
tend to have high scores.
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algorithm For ranking of genes, NetRank combines the expres-
sion level of a gene with the outcome variable of the patient by using
a network of known gene-gene relationships. The ranking might be
computed by eigenvalue decomposition or iteratively. Here, we fol-
low the notation and implementation of Morrison et al. [124], that
defines the ranking of gene j at the nth iteration as follows:
rnj = (1− d)cj + d
N
i=1
wijr
n−1
i
degi
1 ⩽ j ⩽ N (2)
where W ∈ RN×N is a symmetric adjacency matrix representing a
gene network, so wij = wji = 1 if genes i and j are connected, and
otherwise wij = wji = 0. c⃗ is a vector of coefficients representing the
gene expression values with the patients outcome and it is calculated
by foldchange, Student’s t-statistic or correlation (Pearson, Spearman
or Kendall).
Damping factor regulates the
influence of the network
The damping factor d ∈ (0, 1) is a parameter describing the influ-
ence of the network on the rank of a gene. A damping factor of d = 0
corresponds to no influence of the network and full influence of the
gene expression data, whereas setting d = 1 corresponds to full influ-
ence of the network and no influence of the gene expression data on
the rank value of that gene. The value d = 0.85 appears to be used
by Google [137]. The rank of a gene depends on the rank of all genes
that connect to it. Scaling by 1/degi in the summation ensures that
each gene has equal influence in the voting procedure. Each gene gets
a rank of 1− d automatically and also gets d times the votes given by
other genes.
The damping factor is set
dynamically for each dataset
The parameter d is here set as part of the Monte Carlo cross-
validation workflow. For NetRank, we added an additional inner
cross-validation loop. In this inner cross-validation, a part of the
training set samples were excluded, and different values of d ranging
from 0 to 1 in steps of 0.1 were used to run NetRank on the remaining
training set samples. Accuracies of the top-ranked genes were later
tested on the samples previously set aside. As a result of this inner
cross-validation, one d value was chosen and used once for deriving
a signature using the whole training set, and then evaluating its ac-
curacy on the test set. It is important to note that no information of
the test set is used for selecting d, so the choice of a value for d in
the inner cross-validation does not rely on any prediction accuracy
in data of the test set. Furthermore, the optimal d value for each
cancer dataset is dynamically identified by applying the inner cross-
validation step. The dynamic setting of d is a novel improvement of
the NetRank algorithm.
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Figure 5: The detailed
workflow of NetRank. First
the full dataset is randomly
divided into the training and
test set, and the test set is
put aside and later used for
validation (2). While apply-
ing NetRank on the initial
training set, the genes are
ranked by how different they
are between patients with
poor and good prognosis (3)
and the most different genes
are selected (4). These genes
are used to train a classifier
on the training set (5), which
is used to predict the out-
come of the remaining test
set patients (6). The predicted
outcome is compared to the
real outcome and the number
of correctly classified patients
is noted (7). Steps 2-7 are
repeated up to 500 times and
a final accuracy is obtained
by averaging over the 500
runs. The figure is adapted
from [196].
detailed description of netrank A detailed overview of the
pipeline can be found in Figure 5. First the full dataset – a gene
expression matrix, with genes as rows and patients as columns (1) –
is randomly divided into a training and test set, where the test set
is exclusively used for validation (2). For a dynamical setting of the
damping factor, the training set is again randomly splitted (2a - d)
and the best damping factor is found via a cross-validation procedure
for the initial split. While applying the best damping factor on the
initial training set, the genes are ranked by how different they are
expressed between patients with poor and good prognosis (3) and
the genes with the highest variance are selected (4). These genes
are used to train a classifier on the training set (5), which is used
to predict the outcome of the remaining test set patients (6). The
predicted outcome is compared to the real outcome and the number
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of correctly classified patients is noted (7). Steps 2-7 are repeated up
to 500 times and a final accuracy is obtained by averaging over the
500 runs.
3.1.1 Monte Carlo cross-validation workflow
To get a robust estimate on the classification error rate, we adopted
the multiple random validation strategy described by Michiels et al.
[120]. Given a fixed signature size n and a feature selection method,
the following steps were repeated 500 times:
1. The patients of the dataset are randomly split into training and
test sets. The splitting is balanced such that the numbers of poor
and good samples in the test set are either equal or differ by at
most one. This is to ensure that there is no over-representation
of one of the groups in the training set.
2. Using the training set data only, features are ranked according
to a feature selection method.
3. The top-ranked n features are selected and these features be-
come the signature.
4. The signature from the training set is used to train a classifier
on the sample outcome, using the training set expression values
of the signature genes as input.
5. The classifier is used to predict the outcome of the unseen test
set patients.
6. The predicted outcome is compared with the true outcome. The
fraction of correctly predicted patients defines the accuracy.
For the dynamical setting of the damping factor, additional steps are
taken between step 2 and step 3. The overall classification accuracy
is the average of all repeated workflow accuracies. In order to ensure
maximally comparable results, the random splits into training and
test sets were carried out once and the sets were recorded. Thus, the
exact same training and test sets were used for each method applied.
3.1.2 Poor and good prognosis
Patients in the datasets were divided into two groups based on their
clinical outcome. The patients were separated into groups regarding
the median survival time, if no classification was already given in
the publications. In that sense poor prognosis reflects a survival or
response time less than a certain time threshold (e.g., 3 or 5 years),
whereas patients who survive longer than the median survival time
are classified into the good prognosis group.
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3.1.3 Feature selection method
For a prognostic signature, genes with high variance between the
classified groups/samples were selected. To evaluate the strength of
difference following options were compared: (i) foldchange, as de-
fined by the ratio of mean gene expression in one group over the
other group, (ii) the Student’s t-statistic, (iii) the Pearson as well as
the Spearman rank correlation coefficient of gene expression with sur-
vival time of the patient.
3.1.4 Classification procedures
A prognostic model with 10 signature genes was developed by em-
ploying Support Vector Machine (SVM) based learning [158]. Sup-
port vector machines are powerful machine learning algorithms for
classification problems [25, 158, 186]. A SVM was used to classify
the tumors samples into poor or good prognosis groups based on the
expression levels of selected genes. Here, the LIBSVM implementa-
tion is employed as provided in the R package e1071 (version 1.5-18,
obtained July 2010). The expression of each gene was used as an in-
dependent feature to train the classifier and no kind of aggregation
was applied. All feature selection and machine learning steps were
subjected to Monte Carlo cross-validation, which is a recommended
and relatively unbiased evaluation strategy [26, 120].
3.2 preprocessing and filtering of the micro-
array data
For some datasets in the benchmark dataset raw microarray data were
available. Therefore, Affymetrix raw probe level intensity files were
background - corrected, normalized, and summarized using RMA.
The goal was to find a small number of reliable markers, so we do
not want any candidate markers fall into one the categories of (i) low
variance between all samples and therefore not discriminative, (ii) de
facto not expressed, or (iii) expressed at very low levels and thus
not reliably measured in our microarray data. This is achieved by
the filtering steps described in the following. Note that for NetRank,
filtering out meant actually not removing, but setting initial values to
zero in order to prevent loss of edges from the network due to node
removal.
First, to remove noise from genes with low expression, probe sets
with a mean expression below 6 on the scale were filtered out from
the dataset. Second, genes whose expression shows little variation
between patients are not informative as they cannot discriminate be-
tween patient groups. Therefore, probe sets with a standard deviation
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below 0.5 on the scale were filtered out. One gene or EST is normally
represented by one to several probe sets. Thus, we decided to keep for
each gene only the probe set with the highest mean expression over
all patients. We generally found a high correlation between probe
sets reporting for the same gene.
3.3 accuracy
Accuracy is the percentage of correctly classified samples and it is
defined as the proportion of true predictions to all samples. If no
prediction accuracy is stated in the original study, we calculated it by
using the following equation:
accuracy = sensitivity * prevalence +
specificity * ( 1 - prevalence)
where the prevalence is determined as
prevalence = no. of ill persons in that dataset divided
by dataset size.
3.4 signature similarity
Signatures A and B are compared by Jaccard index, i.e. the size of the
intersection of A and B divided by the the size of their union.
JI = |
A

B
A

B
|. (3)
The p− value of each Jaccard index is calculated by the Fisher’s exact
test (fisher.test in stats R package). This test exploits the probability of
an overlap between signatures by chance. In order to provide a better
visualization of statistically significant Jaccard indices, the p-values
are converted into −log(p− value) values in the heatmap plots.
3.5 classical approaches
Classical approaches for gene expression analysis aim in finding dif-
ferences between outcome groups without using any prior knowl-
edge. Many such techniques exist for the identification of genes that
are differentially expressed between conditions. The used method
can greatly influence the set of genes identified. Despite the huge va-
riety of possible methods, there exist two most often used techniques,
the t-test and foldchange, presumably because of their simplicity and
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interpretability. It has been shown that foldchange results in more re-
producible gene list than the t-test [160, 161]. Witten and co-workerss
compared these two strategies on real and simulated data. They con-
clude, that ’there is no correct answer as to whether fold-change or
the modified t-statistic should be used.’ It depends on whether the
interest lies in an absolute change of gene expression or in the change
in gene expression relative to the underlying noise in the gene [197].
Both methods were applied as implemented in the genefilter R
package. In order to select significant genes we did not apply ei-
ther a cutoff threshold or a multiple correction test. After calculation
of these measures, low expression and low variance genes from the
potential signature set were filtered out. All signatures and accura-
cies for the classical methods were obtained by the same Monte Carlo
cross-validation workflow as applied in the NetRank.
3.5.1 foldchange
The foldchange is a measure that describes the quantity of changes
between different values. Genes that differ by more than an arbitrary
threshold are then considered to be differentially expressed. In the
classical microarray analysis these values are normally represented
as the mean of the different outcome groups [180]. As the expres-
sion data is log2 transformed during preprocessing, the foldchange
is defined as:
fc =
xt
xc
(4)
Where xt represents the mean of the gene expression of patients in
the treatment group and xc the mean gene expression of patients
in the control group. Despite its simplicity, the foldchange method
exhibits several disadvantages. First, the variability of variances is
ignored as the foldchange only considers mean values. This results
in genes with large variances passing the cutoff just because of noise.
Second, to call a gene differentially expressed a certain threshold has
to be chosen, without having an indicated level of confidence. Any
chosen threshold therefore remains somewhat arbitrary, and biologi-
cally relevant changes in expression might be happening below this
cutoff, leading to false negative results. To overcome these problems,
the t-test can be applied.
34 methods
3.5.2 t-test
The t-test is a statistical hypothesis test, that follows the Student’s t
distribution if the null hypothesis is supported. It assesses whether
the means of two groups are statistically different. It does so by judg-
ing the different means relative to the spread of variability.
t =
signal
noise
(5)
=
difference between group means
variability of groups
(6)
=
xt − xc
vart
nt
+ varcnc
(7)
This equation does only work for parametric data. For data with
unequal variance the so called Welch t-test has to be applied.
3.6 random signatures
We created 1000 different random signatures with the size of 10 genes
for each dataset. These signatures were created by randomly selecting
10 genes out of all genes in each dataset. We then tested the outcome
prediction accuracy of random signatures via the same Monte Carlo
cross-validation as applied on NetRank on each dataset.
3.7 networks
For the exhaustive testing of NetRank four types of networks are
employed. For the main analysis HPRD [146] and Transfac [119] are
used. Later, the analysis is extended by using STRING [63] and hPrint
[56].
Genes and nodes in networks are represented by Entrez gene iden-
tifiers, therefore probes with unknown Entrez identifiers were dis-
carded.
TRANSFAC TRANSFAC is a manually curated database. It provides data on
eukaryotic transcription factors, their genomic binding sites and reg-
ulated genes. The content is centered on the interaction between tran-
scription factors and their DNA binding sites. It further contains
information about the structural and functional features of the tran-
scription factors. Transfac consist of 2.400 genes and 5.700 interac-
tions.
HPRD HPRD, the Human Protein Reference Database, integrates infor-
mation from domain architecture, post - translational modifications,
interaction networks and disease association for each known human
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protein. The information is as well manually curated from literature
and contains roughly 12.300 genes and 41.300 interactions.
hPrintHPRINT contains predicted physical and functional interactions.
It uses a sophisticated combination of random forest and Bayesian
learning approaches in order to integrate various data sources like
text mining, genetic relationships, evolutionary information as well
as domain profiles. By using this ensemble of evidences hPrint pre-
dicts protein-protein interactions and integrates those predictions
with known information. To keep only high confident interactions
and to remove the majority of false positives, the network was filtered
with a confidence score of 0.7 leading to 12.800 nodes and 236.000
edges.
STRINGSTRING is a database of known and predicted protein interac-
tions. Interactions included are either direct (physical) or indirect
(functional) associations and are derived from different sources: high-
throughput and/or co-expression experiments, textmining as well as
downloaded from existing databases. To have high confidence inter-
actions, STRING was filtered and only interactions with a confidence
score greater than 800 were used, which lead to 11.700 nodes and
342.000 interactions. The confidence score is based on an internal val-
idation. Higher scores lead to sparse networks, whereas lower scores
contain many false positives interactions.
3.8 direct neighbor method
The direct neighbor method averages a gene’s correlation coefficient
over its direct neighbors. Similar to NetRank, the direct neighbor
method starts with an undirected gene network W (represented by
a symmetric adjacency matrix with wij = wji = 1 if genes i and
j are connected, and wij = wji = 0 otherwise) and a gene vector
c⃗ with absolute Pearson correlation coefficients of gene expression
values with the patient survival time. The rank ri of a gene i is then
determined by
r⃗ = (Wc⃗/deg⃗w) (8)
where deg⃗w denotes the degree of the matrix W.
3.9 dataset extraction
Through a comprehensive Medline search previously published mRNA
expression datasets covering different cancer classification scenarios
were obtained.
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More than five hundred publications matching the following query
were extracted on the 1.April.2011:
(cancer[tiab] OR neoplas*[tiab] OR tumor[tiab]) AND
humans[MESH] AND
"gene expression"[tiab] AND
2002:2011[pdat] AND
(marker[tiab] OR biomarker[tiab] OR signature[tiab]) AND
(predict*[tiab] OR diagnos*[tiab]) AND
(survival[tiab] OR outcome[tiab] OR progression[tiab] OR
response[tiab] OR metastasis[tiab] OR behavior[tiab])
NOT (networks[tiab] OR pathway[tiab] OR review[pt] OR
"Tissue Array Analysis"[MeSH Terms] OR
"Protein Array Analysis"[MeSH Terms])
To only retain high quality papers, we selected publications in jour-
nals with impact factor > 5. The remaining 239 articles are screened
manually. For the majority of publications no data was available. The
most widely used chips were HGU133plus2 and HGU133A. For the
sake of comparability, only papers using these chips are retained. For
a reliable accuracy calculation, a cross-validation step is included in
the evaluation. Therefore, only datasets with more than 20 patients
are included in the benchmark dataset. This stringent filtering re-
sulted in 25 suitable datasets.
4 P E R F O R M A N C E O F N E T R A N K
In the following chapter NetRank is evaluated on a benchmark data-
set. First, the benchmark dataset is described in great detail. Second,
certain parameters that might influence the outcome prediction accu-
racy are investigated. Then, NetRank is applied on the benchmark
dataset and its performance is compared to the original studies and
classical methods. Finally, some general findings are discussed as
well as the complexity of NetRank evaluated.
4.1 benchmark dataset for evaluation
In the next section the benchmark dataset is analyzed regarding the
cohort and signature size, the different cancer types covered and the
different methods used. Finally we test, whether the datasets are
representative for all microarray datasets.
Previously published mRNA expression datasets covering differ-
ent cancer classification scenarios were obtained by a comprehensive
Medline search. More than five hundred papers matching the query
were extracted. After a stringent filtering process (see section 3.9), the
benchmark dataset consists out of 25 suitable datasets summarized in
Table 4. For comparison, also an in-house dataset was added [196].
Benchmark dataset reflects
estimated cancer cases
benchmark dataset is representative In 2013 there are 1.6 Mio.
estimated new cancer cases in the United States [165]. Siegel and co-
workers separated the cancer types into 16 different groups. Our
benchmark dataset covers the biggest groups including cancer occur-
ring in the genital, respiratory and digestive system. Figure 6 shows
the frequency of cancer types in our benchmark dataset and the num-
ber of estimated new cancer cases in 2013. The remaining 6 cancer
groups – regarding Siegel et al. - Bones & joints, Soft Tissue, Eye &
Orbit, Endocrine system and Myeloma as well as unspecified cancers
– cover only 8% of the overall new estimated cancer cases. Therefore,
our benchmark dataset is representative as it covers the majority of
all cancer types.
Signature and cohort size varies
in benchmark dataset
Figure 7a shows the distribution of the signature and cohort size in
the benchmark dataset. In cancer outcome prediction a small signa-
ture size is desirable as it can be easily tested in clinical settings via
RT-PCR or immunohistochemistry. The optimal signature size has
not been investigated yet, and it remains unclear if there is any best
signature size. The size of the optimal signature might depend on the
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Table 4: The resulting 26 datasets are covering 13 cancers, four outcome
tasks, and different cohort sizes.
Author Year Cancer Var. #Pat. Sig.size Acc†
Jones et al. [90] 2005 Renal cell S 69∗ 30 100
Spira et al. [168] 2007 Lung D 129 80 82
Lee et al. [104] ⋄ 2010 Bladder P 165 1 79
Steidl et al. [170] 2010 Lymphoma T 130 86 77
Bhojwani et al. [20] 2008 Leukemia
T 82 24 74
P 59 41 73
Bogunovic et al. [22] 2009 Melanoma P 38 50 74
Raponi et al. [149] ⋄ 2006 Lung P 129 50 64
van de Vijver et al. [191] ⋄ 2002 Breast P 295 70 62
Wang et al. [192] 2005 Breast P 276∗ 76 62
Korkola et al. [96] 2009 Germ cell P 82∗ 140 60
O’Donnell et al. [132] 2005 Oral cavity P 27∗ 116 100⋆
Friedman et al. [65]⋄ 2009 Leukemia P 68 180 65⋆
Landemaine et al. [100]⋄ 2008 Breast P 23 6 -
Nanni et al. [127]⋄ 2006 Prostate D 30 20 -
T 20 30 -
Iqbal et al. [86] 2010 Lymphoma D 80∗ 52 -
Fernandez et al. [59] 2010 Lymphoma S 22∗ 13 -
Frank et al. [64] 2006 Leukemia T 41∗ 128 -
Smith et al. [166] 2010 Colon P 55 34 -
Lenz et al. [106] 2008 Lymphoma T 414 357 -
Mok et al. [122] 2009 Ovarian P 53 11 -
Dressman et al. [52] 2006 Breast S 37 22 -
Murat et al. [125] 2008 Glioblastoma T 70∗ 20 -
Zhu et al. [206] 2010 Lung P 133 15 -
Winter et al. [196] 2012 Pancreas P 30 7 -
† Accuracy of the original studies.
∗ A subset of the original dataset was used for NetRank validation.
⋄ These dataset did not provide raw data.
⋆ There is no separation between training and test patients.
clinical variables: D – Diagnosis, P – Prognosis/Progression, S – Subtyping, T – Treatment
Response/Outcome.
Figure 6: Frequency of can-
cer types in our benchmark
dataset and the number of es-
timated new cancer cases in
2013. Siegel and co-workers
separated the cancer types
into 16 different groups [165].
Our benchmark dataset cov-
ers the biggest groups includ-
ing cancer occurring in the
genital, respiratory and diges-
tive system.
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(a) Cohort and signature size (b) Outcome variable
Figure 7: Patient and signa-
ture size (a) as well as fre-
quency of outcome variables
(b) in the benchmark dataset.
(a) The cohort and signature
size in the benchmark data-
set is in average 103 and 65,
respectively. (b) The major-
ity of studies in the bench-
mark dataset are predicting
the prognosis of a patient.
biological question underlying a certain study as well as the desired
prediction accuracy. The datasets in the benchmark dataset discov-
ered signatures containing from one to 357 genes, having 65 genes in
average.
The benchmarks datasets contain in average 103 patients, reaching
from 20 up to 414. There have been several studies correlating the size
of the cohort with the predictive power of the resulting signatures [31,
55]. They show that studies analyzing more than 50 patients result
in better predictions. Having less than 50 patients a systematic im-
provement is possible using bootstrapping [31]. The question arises,
whether these correlations can be also found in our benchmark data-
set and if the cohort size also correlates with the prediction accuracy.
Four different outcome variables
covered
Four different outcome prediction categories exist in cancer out-
come prediction – Prognosis/Progression, Treatment, Subtyping and
Diagnosis. Figure 7b shows the distribution of the outcome variables
in the benchmark dataset. The datasets differ in the outcome variable.
Disease progression – either death or relapse – is the outcome in 14
studies and therapeutic response in 6 studies. Diagnosis and disease
subtyping is the outcome in 3 studies, respectively. Having different
outcome tasks, the question arises, if there is a correlation between
outcome task and prediction accuracy.
Benchmark dataset covers
variety of statistical methods
In the benchmark studies different computational and experimen-
tal methods were applied for the development of the biomarker sig-
natures.
The studies used one or more of the following methods: Compu-
tational methodologies including Student’s t-statistic (13 out of 26
cases) and its variances (Max-T, fishers exact test, random variance
t-test) as well as cross-validation (mainly leave-one-out) and Cox pro-
portional hazard models (15 out of 26). Less frequently applied meth-
ods are machine learning (ML), mainly Support Vector Machines with
linear kernel, SAM [180] and prediction analysis of microarray (PAM)
[178]. For analysis hardly used methods are chi-square test and prin-
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cipal component analysis (PCA) as well as pathway analysis. Hardly
employed methods are regression like logistic or Bayesian regression
along with partial least square and maximizing R square. Signatures
developed by these studies have been validated by statistical methods
like hazard ratio (HR), receiving operator curve (ROC) values as well
as clustering (mainly hierarchical clustering). Immunohistochemistry
or RT-PCR techniques were applied for experimental validation of the
signatures.
Considering this broad spectrum of statistical methods is there a
correlation between method and prediction accuracy? This question
is difficult to investigate as the overlap of used methods in the original
studies is quite low. To answer this question the same analysis should
be applied on all datasets.
High range of prediction
accuracies in benchmark dataset Accuracies stated in the original studies range from 60% to 100%.
Not all studies used an accuracy measure to prove their performance,
but Hazard ratio. The highest accuracy achieved O’Donnell et al. [132]
for predicting metastasis with 100% (validation based on clustering)
as well as Jones et al. [90] for subtyping renal cell cancer (validation
based on leave-one-out cross-validation). The lowest comparable pre-
diction accuracy gained, 60%, Korkola et al. for predicting 5 year over-
all survival [96].
No network-based methods
applied None of these studies employed network-based approaches and
only 13 studies reported prediction accuracies. However, two of these
studies [65, 132] are not directly comparable to our accuracy calcula-
tion since they did not separate training and test data samples, thus,
only 11 studies with reported accuracies are considered.
Benchmark dataset represents
the average microarray dataset To our knowledge it is the first time that such a benchmark dataset
was used to test network-based prediction methods. We think that
these dataset are good representatives for all microarray datasets, as
they cover such a huge variety of diseases, patient and signature size
as well as statistical methodologies.
4.2 the influence of netrank parameters
NetRank depends on a number of parameters: the choice of the genes’
initial values that spread through the network, the damping factor
which influences the amount of spread, the choice of the network,
and the role of noisy and uninformative genes, which are filtered
out. Next, NetRank’s dependence on these parameters is investigated.
The parameters ’Choice of the initial values’, the ’Influence of the
direct neighbors’ and ’The role of noisy and uninformative genes’
were investigated on only one dataset of pancreas cancer [196].
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4.2.1 Choice of genes’ initial values
For the pancreas cancer dataset the best predictions accuracy was ob-
tained by using the rank correlation coefficient of a gene’s mRNA
level with the survival time. The rank correlation values were then
spread by NetRank through the network. Using these dataset specific
values is the difference to the original PageRank algorithm, which
starts with a uniform distribution of values over all nodes in the net-
work. The question arises, what is happening if the value does not
use this specific dataset-dependent fingerprint, but instead a constant
value so that all genes are apriori equally important or, from another
perspective, if one only relies on network topology?
The initial values influence the
prediction results
We tested this and found a prediction accuracy of 62-65% for sev-
eral training set sizes (ranging from 15 to 28), which is considerably
less than the 72% maximum accuracy of the original NetRank. This
is interesting since it implies that although some improvement is al-
ready gained by focusing on network hubs independent of gene corre-
lations, there is indeed more prognostic information that comes from
the use of concrete expression values linked to clinical data.
4.2.2 Influence of direct neighbors
The PageRank can be viewed as an indication of the likely location of
a random surfer who iteratively traverses the network. At each iter-
ation the surfer makes a step from one node to one of its neighbors
with probability d, while with probability (1− d) he makes a jump
to a random node in the network. In NetRank such a random node
is selected with probability proportional to either the correlation of
the corresponding gene expression with patient survival or the fold-
change and t-test values of the different outcome groups (given by
vector c in Equation 2).
Imagine three nodes A,B,C with edges (A,B) and (B,C). With a
damping factor of e.g. d = 0.3, the probability of making two consec-
utive steps from A to C is 0.3 ∗ 0.3 = 0.09. In consequence, only 9%
of information is moved from A to C over B. Thus, the final ranking
of a node is obtained with information that comes for more than 90%
from initial correlation values and direct neighbors only.
So, how does an algorithm perform that considers only direct
neighbors instead of the whole network? In other words, is the global
network structure needed to judge each gene, or is its local neighbor-
hood sufficient? A variant of NetRank that spreads values only to
direct neighbors was implemented. Each node is ranked according to
the average of the initial node values of its direct neighbors.
To our surprise, as shown in Figure 8, this direct neighbor vari-
ant performed in the pancreas cancer dataset [196] almost identically
to the ranking by Pearson correlation (without network information).
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Figure 8: Comparison of
NetRank with a direct neigh-
bor algorithm. The plot
shows the accuracy of a di-
rect neighbor approach that
only takes direct neighbors
into account (as opposed to
NetRank, which considers all
nodes in the network) on
the TRANSFAC network with
different training set sizes.
The direct neighbor approach
performs almost identically
to the Pearson correlation
method (shown here for com-
parison) [196].
Hence, at least for this study, it is important to also consider distant
neighbors. With a sufficiently large number of training samples, Net-
Rank nearly always performs best, but the difference to Pearson cor-
relation and the direct neighbor method becomes sufficiently small.
With few training samples, NetRank and the network only (constant
c value) approach compete for the best accuracy. It seems that the
strength of NetRank is to rely on network topology when data are
sparse and correlation can be misleading, and to shift to relying on
correlation when sufficient data is available.
4.2.3 The role of noisy and uninformative genes
Low expression and low variance genes were initially filtered out
from our microarray data. It is commonly agreed upon that this
is a necessary first step when searching for discriminative genes in
microarray data. But since NetRank is a network-based, integrative
approach, removing genes that could otherwise provide information
for their neighboring nodes is probably a suboptimal strategy. For
NetRank, we therefore keep all genes, but assign an initial value of
zero to those genes that do not pass the filter. This leads for example
to down-ranking of a node that has many neighbors with a value of
zero, but it also allows for up-ranking of a node with an initial value
of zero that has many high value neighbors.
The question if filtering is necessary at all remains. One would
expect NetRank to be robust against “noise” since it uses additional
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Figure 9: Distribution of ex-
pression levels and correla-
tion with survival in four dis-
tinct subsets of the full screen-
ing dataset. (A) Histogram
(density) of gene expression
levels. Our filtering keeps
only the high expression, high
variance genes (red curve).
Sizes of the four subsets are
shown in the upper right. (B)
Histogram (density) of abso-
lute Pearson correlation co-
efficients of gene expression
levels with patient survival.
Since the red and the blue
curve have very similar distri-
bution, ranking by correlation
(which is the starting point for
our NetRank algorithm) will
allow selection of uninforma-
tive, low variance genes (blue
curve) that will impair predic-
tion accuracy when included
in a classifier. Hence, it is
important to filter such genes
out [196].
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network information that can help to detect and ignore noise. To
clarify, our initial filtering actually serves two purposes. It removes
not only noise (genes with low expression that are most likely not
expressed), but also removes uninformative genes (genes that have
low variance and thus cannot be used to discriminate between any
classes in the data). Note that uninformative genes can be highly
expressed – in the benchmark dataset, one third of the genes have
high expression, but low variance.
Noise does not affect the
prediction result To separately assess the effect of noisy (low expression) and unin-
formative (low variance) genes on the accuracy, further experiments
with the pancreas cancer dataset [196] were executed. When we re-
moved uninformative genes but kept noisy genes, the resulting accu-
racy was still 71% (compared to 72% in the original filtering). This
suggests that NetRank is rather robust to noise. However, when
we removed noisy genes but kept uninformative genes, the accuracy
dropped to 56%, which suggests that NetRank is not robust at all
with respect to the presence of uninformative genes. Inspection of the
highly ranked genes in this case revealed that the majority of them
were uninformative high expression, low variance genes. As the top
10 genes are used for classification in our SVM, it is not surprising for
the accuracy to drop if more than half of these genes are uninforma-
tive and hence cannot help in classification. A comparison with the
original filtered approach showed that the previous top-ranked nodes
are still found, but that the uninformative nodes score even higher.
NetRank assigns high scores to
uninformative genes So why does NetRank assign high scores to uninformative genes?
There is a simple explanation: the input for NetRank is not gene
expression values, but the genes’ correlation with survival, the fold-
change or the t-test between two outcome groups. So besides the
network, the basis for ranking a gene is not its expression value. For
the pancreas cancer dataset, the distribution of the correlation coeffi-
cients in four different groups (low/high expression/variance) is plot-
ted. As Figure 9B shows, highly expressed uninformative genes have
very similar correlation coefficients compared to informative genes.
It is virtually impossible for NetRank to detect if a gene will be unin-
formative for classification, as it can have an equally good correlation
value than an informative gene. The fact that many highly expressed
low variance genes are apparently correlated with survival suggests
that either Pearson correlation is not an ideal measure here, or that
the number of samples is too small to give a higher correlation sig-
nal in the informative genes. Since Spearman rank correlations show
a similar pattern, we believe that the latter is true and that for this
dataset size filtering is the best strategy.
Before running NetRank
uninformative genes have to be
filtered out
To summarize, while NetRank is rather robust against noisy low
expression measurements, it is essential to filter out uninformative
genes (i.e. set their initial values to zero) before running NetRank.
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Figure 10: NetRank accu-
racy versus damping factor.
The damping factor measures
network influence. The fac-
tor is optimized for each data-
set. Overall, stronger network
influence leads to better ac-
curacy improvements (corre-
lation r = 0.62). Note: The av-
erage NetRank accuracies of
the datasets were taken as the
base in this plot.
4.2.4 Network influence - Influence of damping factor d on NetRank
results
As discussed in the Introduction section, one objective is to assess the
influence of the network on the outcome prediction accuracy. The
PageRank algorithm applied by Goggle search engine uses a damp-
ing factor of 0.85. In contrast, in NetRank’s random surfer model, the
damping factor d is optimized for each individual prediction task,
and thus allows judging the network influence. With a d = 0, the
surfer never follows links and hence the network topology has no
influence, whereas a d = 1 implies a surfer who only follows links
without randomly restarting and thus increases the importance of the
network. As the damping factor is not a pre-defined parameter as in
original PageRank algorithm, the best damping factor for each data-
set is dynamically set as a part of the Monte Carlo cross-validation
workflow and ranges from 0 to 1 in steps of 0.1. Figure 10 shows the
accuracy improvement of NetRank over the classical approaches plot-
ted against the best damping factor for each literature derived dataset
in the benchmark dataset. The figure shows a slight bimodal distribu-
tion as either a low (0.1− 0.2) or a high (0.7− 0.9) damping factor has
been chosen as the best one. For 12 of 25 datasets, d is < 0.3 and for
5/25 datasets d is > 0.7. Therefore, no single damping factor value
that yields the best results for all datasets was found. This implies
that the underlying networks are not of equal importance in all tasks.
One reason could simply be that current interaction networks are still
sparse and cover only a small fraction of all interactions, hence impor-
tant malignant genes might not be connected.
Damping factor correlates with
accuracy improvement
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Table 5: Damping factors sorted regarding cancer type. There is no repre-
sentative damping factor for a certain cancer type.
Cancer type Best d-values
Breast cancer 0.3 , 0.5, 0.7, 0.9
Lymphoma 0.1, 0.2, 0.2, 0.3
Lung cancer 0.2, 0.7, 0.8
Leukemia 0.1, 0.1, 0.8
HPRD‘s 40 000 interactions and Transfac‘s 5700 represent only a
small fraction of the estimated 650 000 interactions of the human in-
teractome [171]. If the coverage of the network is a key factor, then
one would expect a correlation between the damping factor and the
accuracy improvement. This is indeed the case with a correlation of
r = 0.62, meaning by improving network coverage, outcome predic-
tion results will be increased. Besides, Transfac and HPRD might
include spurious interactions due to the errors in high-throughput
experiments, however such errors are less important than false inter-
actions predicted by text-mining methods [189, 195]. Under the as-
sumption of independence of experimental errors in expression and
interaction data, the outcome prediction is clearly improved by using
network information. This further implies that if NetRank performs
similar to the applied standard methods in selecting disease-relevant
genes, current networks poorly cover disease interactions. Regarding
the networks, selection of the damping factor does not show a re-
markable difference between the transcription factor-target network
(Transfac) and a protein-protein interaction network (HPRD).
No unique damping factor as for
Google’s PageRank
As there is no single damping factor value that yields the best re-
sults for all datasets, maybe there is a cancer-specific damping factor,
which obtains the best prediction performance for a certain type of
cancer? Table 5 summarizes the damping factors for 4 cancer types
occurring more than three times in our benchmark dataset. Breast
cancer and lymphoma as well as lung cancer and leukemia are inves-
tigated in 4 and 3 datasets, respectively. The lymphoma datasets [59,
86, 106, 170] obtain the best results with a relatively low damping fac-
tor between 0.1 and 0.3. Indicating, only little network information is
needed to reliable predict the patients in the datasets. Nevertheless,
no damping factor is in general representative for a certain cancer
type.
A higher damping factor
indicates strong network
support
In datasets having a small damping factor the network information
could not help to improve the prediction accuracy, whereas in data-
sets with a high damping factor the network information drastically
improves the prediction results. The reason could be the quality and
the strength of the signal in the dataset. In datasets with a strong sig-
nal as well as with low noise levels no network information is needed
for a good outcome prediction performance. For example in the Jones
et al. [90] dataset the damping factor is 0.1, indicating a small influ-
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ence of the network on the results. Similar to the original results,
predicts NetRank the different outcome classes with high reliability
(100 and 97% accuracy, respectively). In contrast, in the van de Vijver
et al. [191] dataset a damping factor of 0.7 shows, that quite some net-
work information is needed to boost the prediction result from the
original 62-70%.
As a result of the missing of a general damping factor, the dynami-
cally setting of the damping factor has to be maintained for each new
dataset.
4.3 evaluation of netrank
After assessing the influence of several parameters on NetRank, we
are now evaluating the performance of NetRank on the benchmark
dataset. Therefore, first, the accuracies obtained with NetRank are
compare to the accuracies of random predictors as well as to classi-
cal methods for outcome prediction (t-test and foldchange). Second,
the difference of NetRank and the original results of the benchmark
dataset are measured and finally, the performance of NetRank is com-
pared to other network-based methods. A summary of the results can
be found in Table 6.
This initial analysis is followed by a second analysis incorporating
two larger networks. These networks are evaluated on a subset of the
benchmark dataset.
Note that the analysis is based on compact signatures consisting of
only 10 genes.
4.3.1 NetRank and random predictors
We created 1000 different random signatures for each dataset con-
tained in the benchmark dataset. These signatures are created by
randomly selecting 10 genes out of all genes in each dataset. The out-
come prediction accuracy of the random predictors is assessed via a
Monte Carlo cross-validation on each dataset.
NetRank outperforms random
predictors
As expected, the NetRank algorithm performs better than the ran-
dom predictor in all datasets, with one exception of the ovarian can-
cer dataset of Mok et al. [122]. Signatures obtained via network-based
as well as signatures from classical approaches perform in this spe-
cial dataset like random signatures. Signatures obtained via t-test
achieve even a performance that is ten percent worse compared to
random. In the remaining datasets, our network-based method is in
average 13.5% better, ranging from 3 percent improvement up to 40
percent.
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4.3.2 NetRank and classical approaches
We explored the Student‘s t-test and foldchange as classical meth-
ods. Both methods are applied as implemented in the genefilter R
package. Foldchange finds the log ratio of the means of gene expres-
sion for two outcome classes. The t-statistic measure provided by the
Student‘s t-test shows the difference between two class means by con-
sidering expression variance of the classes. More information about
t-test and foldchange can be found in section 3.5. In order to select
significant genes, we did not apply either a cutoff threshold or mul-
tiple correction tests. NetRank outperforms the classical methods
NetRank outperforms the
classical methods
in all datasets, except in the lymphoma dataset of Steidl et al. [170]
and the Leukemia dataset of Friedman et al. [65], where NetRank per-
forms as good as the classical methods in average. In the remaining
datasets the network-based methods is in average 7.25 percent points
better, ranging from one to twenty percent.
4.3.3 NetRank and original results
None of the authors of the 25 datasets employed network-based ap-
proaches and only 13 studies reported prediction accuracies. We con-
sidered only 11 studies with reported accuracies due to no separate
training and test samples in two studies [65, 132]. How does NetRank
compare to these studies? Caution must be taken here. First, the au-
thors’ own computation of accuracy may not be directly comparable
to our definition. Second, most of the reported accuracies are sub-
Original results are better than
classical methods
stantially better than classical methods. In nine out of eleven studies
the published prediction results are better than the classical meth-
ods with an average improvement of 9%. This indicates that most
of the authors apply advanced analysis methods in the selection of
signature genes. For example, Steidl et al. applied a sparse multino-
mial logistic regression to construct signatures in combination with
clinical variables [170]. Bogunovic and co-workers derived a predic-
tive signature by using principal component analysis [22]. Lee et al.
assigned E2F1 as the predictor gene to identify the invasive progres-
sion of bladder tumors by using up-modulated gene expression and
prior knowledge [104].
The purely computational
approach of NetRank approaches
the level of the authors’
signatures
Nonetheless, we compared NetRank to the author accuracies: For
three out of eleven datasets NetRank is better, but on average Net-
Rank is two percent worse. The difference ranges from -12 up to 11
percent accuracy points. This indicates that NetRank‘s improvement
over classical methods is approaching the level of the authors‘ signa-
tures. Taken together, a fully automated network-based approach –
like NetRank – is able to obtain similar results as the hand-selected
signatures of the authors.
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In the renal cell cancer dataset of Jones et al. the signal seems to
be really strong as it could be captured by the authors as good as by
NetRank [90]. Both methods achieved close to 100 percent prediction
accuracy.
4.3.4 NetRank and other networks
For further evaluation of the influence of different networks, we ap-
plied NetRank to two larger networks: STRING and hPrint.
Table 7 shows the results of 13 datasets on these two networks. The
four networks deliver similar prediction performances as the accu-
racies lie between 71− 75%. Transfac performs slightly better, as it
obtains an average prediction accuracy of 75.7% in comparison to
HPRD, hPrint and STRING, which result in an average accuracy of
74.2, 73.9 and 71.4 percent points, respectively. The superior perfor-
Transcriptional information
especially suited for outcome
prediction
mance of Transfac suggests that regulatory information is particularly
suited for outcome prediction. Most cancer types arise due to muta-
tions in regulatory elements, therefore the efficiency of Transfac in
cancer outcome prediction is biologically reasonable.
The accuracies between the different networks do not show a high
variance, except for the dataset of Fernandez et al. [59] and Dress-
mann et al. [52]. In the lymphoma dataset of Fernandez et al. the
STRING networks results in an accuracy 16% worse compared to the
average of the remaining networks. The hPrint network outperforms
the networks and lead to an accuracy of 87%. In the breast cancer
dataset of Dressmann et al. the result is different. STRING, hPrint
and HPRD result in an accuracy of around 54%, whereas Transfac
obtains a prediction accuracy of 64%.
4.3.5 NetRank and other network-based methods
NetRank provided better outcome predictions compared to non-net-
work-based methods, hence it is an interesting question whether
other network-based methods also lead to improvements. To test this
hypothesis, the prediction performance of NetRank is compared with
other network-based methods [36, 42] on two breast cancer metastasis
datasets [191, 192].
The dataset of Wang et al. [192] employs the expression of 22.000
transcripts from total RNA of frozen tumor samples. The datasets
contains 286 lymph node- negative primary breast cancer samples
that is composed of 77 estrogen-receptor negative (ER-) and 209 estro-
gen-receptor positive (ER+) samples. The gene expression profiles
were analyzed with Affymetrix Human Genome U133A Array. The
van de Vijver et al. [191] gene expression dataset consists of 295 sam-
ples, including 151 lymph node-negative disease and 144 lymph node-
positive disease. There are approximately 25,000 human genes tran-
scribed and labeled to self-made microarrays for each sample.
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In this comparison, NetRank accuracies based on Transfac are used
and the accuracies from the two network-based methods are taken
from the respective publications [36, 42].
Both methods integrate gene expression and network data sets.
approach of chen et al. Chen and co-workers work with net-
work-constrained support vector machines [36]. Their proposed meth-
od adapts the assumption that hub genes are usually expressed with
low variability which requires the incorporation of network informa-
tion to improve generalizability of the results. Therefore, the network
information is explicitly formulated as a Laplacian matrix and em-
bedded into the objective function of SVM for optimization. This
leads to an improved classification as the contribution of hub genes
to the SVM is greatly enhanced; even hub genes not significantly dif-
ferently expressed between two phenotypes influence the resulting
hyperplanes. Significant genes or subnetworks are detected through
a significance test based on label permutation.
approach of chuang et al. In the approach of Chuang et al. [42],
a candidate subnetwork is scored to assess its activity in each patient.
The assessment of a subnetworks activity is based on averaging its
normalized gene expression values. Afterwards, for each subnetwork
the discriminative potential is measured based on the mutual infor-
mation between its activity score and the metastatic/non-metastatic
disease status over all patients. To identify significantly discrimi-
native subnetworks, their discriminative potentials are compared to
those of random networks. In their study, Chuang and co-workers
apply their method on breast cancer patients in two data sets.
Results
All network-based methods
perform comparable
The prediction results of the three network-based methods on two
breast cancer datasets are shown in Table 8. All three methods per-
form comparably well in both breast cancer dataset in comparison
to non-network-based approaches The approach of Chuang et al. is
slightly superior with 2% and 5% percent points in the dataset of van
de Vijver et al. and Wang et al., respectively. Chuang and co-workers
achieve a similar accuracy to NetRank, but outperform regarding sen-
sitivity. They achieve in both breast cancer datasets a sensitivity of
90%. In comparison to Chen et al., our approach has similar predic-
tion accuracies but showing better sensitivity scores. These variances
in the sensitivity and specificity measures of the three network-based
methods might be caused by the usage of different machine learning
methods and cross-validation procedures during the training of the
classifiers.
In comparison to the classical methods, all three network-based
methods improve the prediction result. The methods are in the data-
set of van de Vijver et al.in average 7 and 10% better than foldchange
4.3 evaluation of netrank 53
Table 8: Comparison of NetRank with other network-based methods. All
three methods perform comparable in both breast cancer datasets. The vari-
ances in the sensitivity and specificity measures of the three network-based
methods might be originated by the usage of different machine learning
methods and crossvalidation procedures during the training of the classi-
fiers.
Method Accuracy TPR TNR Dataset
NetRank 68 69 62
van de
Vijver et al.
Chen et al. [36] 65 51 74
Chuang et al. [42] 70 90 63
Foldchange 61 - -
t-test 58 - -
NetRank 67 70 53
Chen et al. [36] 71 42 81
Chuang et al. [42] 72 90 62 Wang et al.
Foldchange 66 - -
t-test 65 - -
and t-test, respectively. In the dataset of Wang et al.the methods out-
perform the classical methods with 4 and 5%.
These results confirm that network information improves outcome
prediction in comparison to the classical methods as well as to the
original results.
4.3.6 Comparison to the related work of Cun and Fröhlich
Cun and Fröhlich applied fourteen different genes selection methods
(eight incorporate network information) on six public available breast
cancer datasets [44]. They could not identify one single of these four-
teen approaches to perform best regarding prediction performance,
which stands in contrast to the results found in this thesis.
KEGG pathway information not
useful for network-based cancer
outcome prediction
Their statement is based on datasets of one kind of cancer – breast
cancer – and one type of network – non-metabolic KEGG pathways.
The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a man-
ually curated database consisting of directed pathways representing
experimental knowledge on metabolism and various other cell func-
tions. The authors combined these information with data from the
Pathway Commons database [34] resulting in a graph consisting of
13.840 nodes and 397.454 edges.
In our analyses transcriptional information – as provided by Trans-
fac – tend to be more suited for outcome prediction than the remain-
ing network types. Directed pathway information is not included
into our analyses, but following Cun and Fröhlich’s results KEGG’s
pathways information does not seem to improve cancer outcome pre-
diction.
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The breast cancer dataset of Wang et al. [192] is included in our
benchmark dataset. Unfortunately, the performance of the algorithm
is stated as area under the curve (AUC) instead of prediction per-
formance, thus results are not directly comparable. None of the eight
network-based methods reached an AUC larger than 0.70, supporting
the hypothesis that KEGG pathway information is not appropriate for
the use in outcome prediction. According to Cun and Fröhlich find-
ings, also our results indicate that for this dataset network informa-
tion in general is not greatly enhancing the prediction accuracy. The
application of network information through NetRank improves the
predicting accuracy only for 3% compared to the classical methods.
In addition only two out of the six non-network based approaches
reached an average AUC of 0.70 and higher.
An algorithm using GeneRank is included into the ensemble of
tested approaches. The algorithm – called Reweighted Recursive Fea-
ture Elimination (RRFE) – identifies significant genes by stepwise
elimination of features [89]. The algorithm is explained in great detail
in subsection 2.2.3. This approach reached an average AUC of 0.67 on
the breast cancer dataset of Wang et al.. On all six breast cancer data-
sets the algorithm performs with an average AUC of 0.63, reaching
from AUC 0.51 – 0.76, making it the network-based approach with
the highest variance in AUC over all analyzed datasets.
The beneficial effect of
background knowledge differs
between datasets
For some datasets the use of background information is more ben-
eficial than for others. In the case of the Wang et al. dataset the
non-network based methods achieve an higher average AUC than the
network-based methods, but the results look different for the breast
cancer dataset of Desmedt et al. where the network-based methods
are in average better than the applied classical non-network based
methods.
Thus, their statement that in general pathway knowledge does not
significantly improve cancer outcome prediction is conclusive, but fol-
lowing our results the picture looks different when applying different
types of protein-protein interaction networks. In addition depends
the beneficial effect of network information on the applied dataset.
Network-based signatures
overlap
In concordance to our results they found the similarity and bio-
logical interpretability of resulting signatures significantly enhanced
using network-based approaches (see chapter 5).
4.4 general findings
In the last section the performance of NetRank is compared with ran-
dom predictors, classical methods and the results of the original stud-
ies as well as to other network-based methods. It has been shown that
incorporation of network information is able to dramatically enhance
the prediction accuracy for different outcome prediction tasks.
In the following section further general parameters are discussed
that might influence the prediction results.
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4.4.1 Physical interactions as good as regulation
For assessing the performance of NetRank, four different networks
are applied: HPRD [146], Transfac [119], STRING [63] and hPrint [56].
The networks differ in type of interaction and size. HPRD covers
physical interactions contains nearly 10.000 genes and 40.000 interac-
tions. Similar in size of nodes are STRING and hPrint. HPrint uses
predicted physical and functional interactions and contains roughly
13.000 nodes and 235.000 edges. STRING with its 11.000 nodes and
340.000 edges is a database of known and predicted protein inter-
actions. The smallest of all four networks is Transfac, which is a
network of transcription factors and targets and has only some 2.400
genes and 5.700 interactions.
As shown in Table 6 and Table 7, there is no substantial difference
in prediction accuracy, while applying NetRank on these networks.
Transfac is better than HPRD in 16 out of 25 cases with an average im-
provement of 1 percent point. Regarding STRING and hPrint, Trans-
fac outperforms in 7 out of 13 datasets, with an average improvement
of 4.3% and 1.8%, respectively.
Transcriptional information best
suited for outcome prediction
Nevertheless, employing only the Transfac network achieves an
equal performance using far less genes. Cancer often arises due to
alterations in transcription factor expression, leading to unregulated
cell growth and differentiation. Therefore, the efficiency of Transfac
in cancer outcome prediction is biologically reasonable. Transcrip-
tion factors have been already discussed as one of the main source of
cancer development [128] as well as suggested as targets for cancer
therapy [47]. This implicates that future regulatory networks lead to
further improvement in outcome prediction.
4.4.2 Influence of cancer bias
Network information is generally extracted from literature studies.
Therefore genes in such networks are often highly related to certain
diseases, e.g. cancer and many biological interaction networks typi-
cally have small diameter due to the presence of ’hub’ genes of high
degree. There are reports that cancer-associated genes have more in-
teraction partners than non-cancer genes [91, 110], and indeed genes
found in NetRank signatures like SP1 have high degree in most inter-
action networks (e.g., the degree of SP1 in Transfac is 421).
In order to assess the impact of the well-studied cancer proteins in
a network, the analysis was limited to these well-studied genes. For
this purpose, genes mentioned in Transfac are solely provided as an
input to the classical methods (foldchange, t-test) and their prediction
accuracy is assessed via leave-one-out cross-validation.
As indicated in Table 9, the prediction accuracies of the classical
methods obtained by this limited gene set are generally lower than
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Table 9: The prediction accuracies of the classical methods (foldchange (FC),
t-test (TT)) by using only Transfac genes. The classical methods select the
signatures from Transfac genes rather than from the entire chip. The Net-
Rank (NR) column shows the prediction accuracy obtained by Transfac. The
results prove that the NetRank algorithm can efficiently use regulation in-
formation by following edge relations in Transfac, hence it provides more
predictive signatures compared to the classical methods. The best result per
dataset is marked in bold.
Author Cancer Var. FC TT NR
Jones et al. [90] Renal cell S 73 77 97
Spira et al. Lung D 67 64 69
Lee et al. [104] Bladder P 59 60 76
Steidl et al. [170] Lymphoma T 70 69 74
Bhojwani et al. [20] Leukemia
T 46 50 64
P 56 47 72
Bogunovic et al. [31] Melanoma P 56 62 70
Raponi et al. [149] Lung P 53 52 59
van de Vijver et al.
[191]
Breast P 63 63 68
Wang et al. [192] Breast P 64 65 67
Korkola et al. [96] Germ cell P 66 66 71
O’Donnell et al. [132] Oral cavity P 75 75 81
Friedman et al. [65] Leukemia P 51 57 55
Landemaine et al. [100] Breast P 67 67 99
Nanni et al. [127] Prostate
D 97 96 99
T 25 40 70
Iqbal et al. [86] Lymphoma D 68 73 82
Fernandez et al. [59] Lymphoma S 38 39 81
Frank et al. [64] Leukemia T 66 67 75
Smith et al. [166] Colon P 62 62 71
Lenz et al. [106] Lymphoma T 60 63 65
Mok et al. [122] Ovarian P 35 35 65
Dressman et al. [52] Breast S 39 36 64
Murat et al. [125] Glioblastoma T 35 36 59
Zhu et al. [206] Lung P 48 47 58
Accuracy %:
30-34 35-40 41-45 45-50 51-55 56-60 61-65
66-70 71-75 76-80 81-85 86-90 91-95 96-100
clinical variables:
D – Diagnosis, P – Prognosis/Progression,
S – Subtyping, T – Treatment Response/Outcome.
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NetRank results based on Transfac. Note, the non-limited results for
all methods can be found in Table 6.
Limited search space leads to
worse prediction results for
classical methods
Limiting the dataset to only well-studied proteins achieves worse
prediction accuracy in 20 out of 25 datasets for foldchange and t-test,
respectively. For foldchange, the result got in average 11% worse for
20 datasets but for five datasets (O’Donnell, Spira, Bogunovic, van
de Vijver, Nanni D) the prediction accuracy improved in average for
4.5 percent points compared to the original non-limited results. In
the lymphoma dataset of Fernandez et al. the accuracy declined for
40 percent points in the limited dataset. It only reached a prediction
accuracy of 38%. In contrast, the accuracy in the oral cavity cancer
study of O’Donnell et al. and the prostate cancer dataset of Nanni
et al. improved drastically for 9% and 8%. In the case of t-test a
similar picture can be drawn. The limited results are in 20 out of 25
datasets worse than the non-limited results. In these 20 datasets the
accuracies declined in average 9%. In the remaining datasets (van de
Vijver, Landemaine, Smith, Lenz, Zhu) the results got in average 3.4%
better. In the limited t-test results, he performance in the lymphoma
dataset of Fernandez strongly declined for 28% and only reached an
accuracy of 39 percent. In comparison, the breast cancer dataset of
van de Vijver and co-workers gained 5% in prediction accuracy.
Cancer bias does not influence
the prediction performance of
NetRank
In general, roughly 75% of all datasets achieve worse prediction
accuracies compared to the full dataset. In datasets already having a
bad performance of around 50%, limiting the gene set to only the well-
studies genes, decreases the accuracy even below the performance of
a random predictor. The remaining datasets keep their prediction
performance.
The results indicate that the information gain achieved by NetRank
is not solely based on well-studied cancer proteins but also on the
interaction between them.
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Figure 11: NetRank accu-
racy vs. outcome task. Diag-
nosis and subtyping are eas-
ier than treatment or progno-
sis. Note: The average pre-
diction accuracies of Table 6
NetRank column were taken
as the base in this plot.
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4.4.3 Prognosis and treatment is more difficult to predict than di-
agnosis and subtyping
Outcome prediction defines the future state of a patient based on its
current disease state and focuses on the following topics: (1) Treat-
ment response deals with the different response types of patients to
treatments. Here, response means a prolonged metastasis-free sur-
vival or faster response to therapy. (2) Prognosis/Progression deals
with cancer development after (3) Diagnosis. Finally, (4) Subtyping
aims to distinguish different subtypes of cancer. Subtypes may al-
ter in the aggressiveness of the cancer along with different spreading
behavior and may end up in different treatment needs.
Figure 11 summarizes NetRank‘s average accuracies of Table 6 for
the four different outcome prediction tasks. As the figure shows, diag-
nosis and subtyping can be predicted more reliable than response to
treatment and prognosis. While datasets that try to diagnose cancer
or predict subtypes have in average an accuracy of around 81%, the
outcome variables treatment and prognosis only result in prediction
accuracies around 66%.
Diagnosis is easier to predict
than prognosis and treatment
One explanation for this result could be that treatment and prog-
nosis depend more on external, non-molecular parameters such as
age, sex or different living conditions. Another possible explanation
is the difference in gene expression between outcome groups. When
diagnosing a malignant disease, healthy and cancerous tissues are
compared. These two types of tissue express highly different number
of proteins [169], whereas in the case of progression and treatment
response prediction, the difference in the gene expressions is very
subtle. In addition, due to the combination of background noise in
microarray experiments and low expression levels, these subtle differ-
ences are not reliably detectable [94], thus resulting in worse predic-
tion performance.
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(b) Accuracy vs. signature size
Figure 12: Accuracy vs. co-
hort size (a) and signature
size (b). Prediction accuracy
does not correlate with the
number of patients (correla-
tion r = −0.14). Nevertheless
the signature size seems to in-
fluence the prediction results
(correlation r = −0.47). The
analysis is based on 11 accura-
cies, which were provided in
the original publications.
4.4.4 Influence of signature and cohort size on the prediction accu-
racy
An interesting question that arises is whether the size of signature
and patient cohort influence the prediction results. Also, a small co-
hort could be prone to more artifacts and hence having a better accu-
racy than a large and more representative study. Hence, we assessed
whether signature size and prediction accuracy are correlated.
As our network-based method always produces signatures with
a fixed length of 10 genes, these issues are explored by using the
original accuracies as provided in 11 publications.
No influence of cohort size on
prediction performance
While investigating the effects of these parameters on the predic-
tion accuracies, no clear correlation could be observed, indicating any
effect of the cohort size on the prediction accuracy. As can be ob-
served in Figure 12a, prediction accuracies are not related to cohort
size as the correlation between these two parameters is −0.14. Bo-
gunovic and co-workers [22] achieve with 38 patients a similar good
performance as Steidl et al. with 130 patients [170]. It has been shown,
that an exact outcome prediction is possible with a small cohort of
only 27 patients [132]. In this study the progression of oral cavity
cancer is predicted with 100% accuracy.
The signature size influences
prediction accuracy
Nevertheless, the signature size – at least in our data – seems to
influence the prediction results. The signature size correlates with
r = −0.47 to the prediction performance. Figure 12b plots the signa-
tures size against the accuracy published by the authors. Smaller sig-
natures tend to have higher accuracies and large signature does not
ensure high prediction performance. Particularly, having the biggest
signature of 140 genes, Korkola et al. performs worst of all benchmark
datasets with an accuracy of 60%. Whereas, Lee et al. [104] obtains
with the smallest signature of one gene an accuracy of 79%.
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4.4.5 Influence of the machine learning method
During experiments, we were faced with the problem of prediction
accuracies significantly lower than 50%. For instance, Support Vector
Machines (SVMs) could not clearly be trained on the Mok et al. [122]
and Nanni et al. [127] datasets. Notably, the few patient samples
(n = 20) in the treatment dataset of Nanni et al. might be a reason
of the poor performance of SVM. Therefore, we assumed that other
machine learning approaches would be more suitable. To assess the
prediction performance of different machine learning approaches, we
trained them using the 10-gene signatures obtained by NetRank in
one dataset and tested them on all other datasets (Figure 5: Steps
5–7). The prediction capability of the four different machine learning
methods is determined and their performance for outcome prediction
is assessed.
decision trees Decision trees (DT) are a classifier, which uses a
tree-like graph to model decisions and their possible consequences.
In a decision tree an internal node represents a certain test on an
attribute, each branch represents the outcome of that test and each
leaf represents the class label. A path from root to leaf represents
classification rules. The tests on the internal nodes can be any other
machine learning method.
k-nearest neighbor The k-nearest neighbor approach (k-NN) is
a non-parametric classification method based on the Euclidean dis-
tance between a test sample and the specified training samples. Due
to a majority vote of its neighbors a test object is classified with the
class being assigned to most of its k nearest neighbors.
linear discriminant analysis Linear discriminant analysis (LDA)
is a commonly used technique for data classification and dimensional-
ity reduction. LDA finds a linear combination of features to separate
two or more classes and is able to handle unequal within-class fre-
quencies. LDA explicitly models the difference between the classes of
data by maximizing the ratio of between-class variance to the within-
class variance in any particular data set.
random forest Random forest (RF) is an ensemble learning tech-
nique that operates by creating a multitude of decision trees by search-
ing over random subsets of trees. To classify a new object, the input
is classified by the trees in the forest and each tree decides a classifi-
cation for the input. The resulting class is defined via a majority vote
of all trees.
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(d) RF
Figure 13: Accuracy
heatmap of transferred
signatures with different
machine learning methods.
Signatures were found with
NetRank on Transfac. Rows
and columns represent the
predictive signatures and
datasets, respectively. So,
the diagonal shows the
accuracy of the signature
on the original dataset. The
accuracies lower than 50%
(worse than a random guess)
are indicated in white color.
Different machine learning
techniques gave different
accuracies. SVMs have an
overall lower accuracy and
fail to predict progression
outcome of [122, 127]. For
our datasets, the k-NN ap-
proach has an overall higher
accuracy than SVM, LDA and
RF (3%, 2% and 2 % average
improvement). Nevertheless
the differences are subtle,
thus the performance of the
different machine learning
methods are comparable
to each other. In addition,
following the no-free lunch
theorem, there is no ideal
machine learning method
providing high classification
accuracy independent of
context and data [53].
Test results
The results for SVM, LDA, k-NN and RF are given in Figure 13. DTs
delivered low prediction accuracies. Therefore the results are not
shown.
For our datasets, the k-NN approach has an overall higher accuracy
than SVM, LDA and RF with 3%, 2% and 2 % average improvement,
respectively. Over all datasets the k-NN approach achieves a predic-
tion accuracy of 63 percent points. It generally outperforms the other
approaches in almost all datasets. The k-NN is in 20, 22 and 22 out
of 25 datasets better than RF, SVM and LDA, respectively. Interest-
ingly, it is consistently worse than the other approaches in the dataset
of Nanni et al. (T) [127] and Murat et al. [125], whereas it predicts
the Jones et al. [90] and Mok et al. [122] dataset persistently better,
with roughly 4 percent points. The signal in the Mok et al. dataset
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seems to be difficult to capture by RF, SVM and LDA as these meth-
ods obtain accuracies around 50% (white squares), whereas the k-NN
approaches is able to handle the data. In general, is the performance
of RF almost similar to LDA.
These experiments show that the prediction performance of the
NetRank could be further improved by using several machine learn-
ing methods. Nevertheless, the differences are subtle. Thus, the per-
formance of the different machine learning methods is comparable to
each other. In the benchmark dataset the average cohort size is 103
patients, so differences in prediction accuracy of one percent lead to
the correct prediction of only one extra patient.
In addition, as stated in the No-free lunch theorem [53], there is no
ideal machine learning method providing high classification accuracy
independent of context and data.
4.5 computational complexity of netrank
In the following section NetRank is analyzed regarding space and
time complexity.
Space complexity
The space complexity of an algorithm is equal to the memory space
used by the algorithm to solve a given computational problem as a
function of the size of the input.
Space complexity grows linear to
the number of edges and patients
For NetRank the patient and network data is loaded into mem-
ory for an efficient calculation, which introduces a memory-related
overhead. The space complexity of the algorithm depends on three
factors: number of nodes in the network (n), number of edges in
the network (e) and number of patients (p). During this evaluation
the number of nodes in the network is constant with approximately
22.000 human genes. Therefore the space complexity grows linear
with the number of edges as well as with the number of patients in
O(e ∗ p).
Memory is the bottleneck As in the protein networks more than 50% of the nodes do not
have edges to any other nodes, the networks are implemented in a
sparse matrix representation, resulting in a matrix primarily popu-
lated with zero. Sparse matrices are conserving space by representing
only the non-zero entries. During calculation the sparse matrix has
to be populated for the matrix-vector multiplication, resulting in an
increased memory usage. In the current version, running the matrix-
vector multiplication with a network of approximately 100.000 edges
consumes at least 2 Gigabyte of memory. For current network sizes,
NetRank can be run on commodity hardware having 4 GB RAM, but
with increasing network sizes this is growing up to terabytes, espe-
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Table 10: The running time of NetRank differs between the datasets, de-
pending on cohort and network size. Table shows maximum running time
in hour per process for datasets having different cohort sizes. Note: Lenz et
al.was not evaluated on STRING and hPrint.
Dataset Cohort Running time for 1 cross-validation
size Transfac HPRD STRING hPrint
Lenz et al. 414 20h 40h - -
Spira et al. 129 12h 25h 57h 63h
Landemaine et al. 23 8h 12h 23h 27h
cially when testing several networks at the same time, thus making
the memory the major bottleneck of the algorithm.
The memory usage of the machine learning algorithms is less sig-
nificant.
Time complexity
The time complexity of an algorithm quantifies the amount of time
an algorithm needs to run as a function of the length of the input.
Quadratic time complexityAt the core of the NetRank algorithm are two important opera-
tions, matrix-vector multiplications and machine learning algorithms.
The machine learning algorithm used during NetRank evaluation are
Support Vector Machines which run in a complexity of O(n) [35] and
the matrix-vector multiplication is done in O(n2) with n being the
amount of nodes in a network. The multiplication is done 500 times
in the outer validation and 500 times in the inner validation for each
damping factor. This sums up to 250.000 matrix multiplications per
task, but does not influence the time complexity. Therefore the com-
plexity of NetRank grows quadratically with the size of nodes.
evaluation time One problem in biomarker discovery is the over-
estimation of prediction performance due to biased signatures. To
overcome the problem of signatures being biased to either the train-
ing or test set, NetRank performs a supervised learning process com-
bined with a Monte Carlo cross-validation scheme to predict bio-
marker genes. Therefore, each dataset is split 500 times. Table 10
shows the running time of NetRank for a single cross-validation on
datasets having different cohort sizes. The evaluation of NetRank on
the biggest dataset of Lenz et al. [106] took 30.000 CPU hours (3.4
CPU years). This estimates to approximately 60 CPU years for the
evaluation of the benchmark dataset on HPRD and Transfac. With
26 datasets – each having roughly 22.000 genes – being evaluated
on two networks (Transfac and HPRD) in a 500 fold cross-validation
procedure 572 million PageRank’s had to be calculated.
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4.6 discussion
Although the first diagnostic assays for cancer outcome prediction
are on the market allowing patients to personalize treatment options,
the criticism remains that large signatures appear random, since other
signatures perform equally well. Here, we aimed to address this prob-
lem by focusing on signatures that are compact (only 10 genes) and
that were obtained with a network-based approach, which puts the
signature genes into a context rather than selecting isolated genes.
Network information improves
cancer outcome prediction
Indeed, we found on 26 datasets – covering different cancers, out-
come tasks and cohort sizes – that there is a consistent and significant
improvement of the network-based approaches over random signa-
tures and a classical approach based on t-test or foldchange. Besides,
we are approaching the accuracy level of the authors’ signatures by
applying a relatively unbiased but fully automated process for bio-
marker discovery.
NetRank performance depends
on damping factor
We furthermore investigated several parameters influencing the re-
sult of NetRank. e.g. how the genes initial values or the damping
factor influences the results. We show that the choice of the damp-
ing factor regulates the influence of the network on the results, as it
balances the impact of expression and interaction on the prediction
result. A weak correlation of d to accuracy improvement was ob-
served, suggesting that increasing coverage of the interactome may
also lead to further improvements in the prediction accuracy. The
novelty of NetRank is the dynamical setting of the damping factor
during signature development. As each dataset has its own dataset
specific damping factor, the dynamical setting has to be maintained
for each new biomarker creation.
Regulatory information best
suited for outcome prediction
An important open question is also the influence of the network
topology on the analysis. We experimented with a regulatory (Trans-
fac) and physical interaction (HPRD) and two predicted networks
(hPrint, STRING). The latter are several orders of magnitude larger
than the first. Nonetheless, all can be considered as a fraction of the
complete interactome that is currently not yet known. Interestingly,
despite the size difference, they perform equally well. This suggests
that regulatory information is particularly suited for outcome pre-
diction. Most cancer types arise due to the mutations in regulatory
elements, therefore the efficiency of Transfac in cancer outcome pre-
diction is biologically reasonable.
Limited search space leads to
worse prediction results for
classical methods
Furthermore, we evaluated the disease bias in networks as genes in
networks are often highly related to certain diseases. We show that
this bias does not affect the prediction abilities of NetRank. In con-
trast, limiting the search space to only well-studied proteins decreases
the result of the classical methods dramatically.
Diagnosis is easier to predict
than progression or treatment
Predicting response to treatment and progression are generally
more difficult than diagnosis and subtyping. We hypothesized that
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the former is more strongly influenced by external factors such as
age and sex. Furthermore, we conclude that for diagnosis the gene
expression signal is much stronger. This can be proven by comparing
the accuracy obtained via random predictors in the prostate dataset
with any other accuracy obtained by more sophisticated methods.
The signal is strong enough to be captured even by random gene
selection.
Signature size influences
prediction performance
Another question was the correlation of cohort and signature size
to prediction performance. On one hand we found a small correlation
of signature size with prediction accuracy, but on the other hand no
correlation for cohort size and accuracy could be observed.
Choice of machine learning
method shows only small impact
on accuracy
Finally, we investigated the influence of machine learning approaches
on outcome prediction. We could clearly observe a difference be-
tween diverse machine learning approaches. Overall, the k-NN ap-
proach performs best. Nevertheless, the differences are subtle and
not statistically significant.
NetRank is efficientFurthermore, the time and space complexity of NetRank scales
quadratically with the input size, resulting in an efficient method for
biomarker discovery.
As a summary, network-based gene expression analysis is leading
to a more detailed understanding of cancer and cancer-related pro-
cesses by selecting highly relevant genes that are not just correlating
with but actively influencing the outcome of a patient. Furthermore,
putting prognostic signatures into the context of pathways and net-
work neighborhood may provide crucial information to move from
biomarkers to targets, whose modulation will influence outcome.

5 U N I V E R S A L C A N C E R
S I G N AT U R E
Single gene markers express several drawbacks and cannot reliably
be used for cancer outcome prediction. For this reason several ap-
proaches use selections of predictive genes. Nevertheless, the overlap
of these gene sets tends to be zero, even for the same outcome task.
In this chapter signatures obtained by original publications, greedy
methods as well as NetRank are analyzed regarding their similarity.
The overlapping genes of NetRank are furthermore analyzed for their
biological context and meaningfulness. The similarity of signatures
between several cancer types direct towards a Universal Cancer Sig-
nature. This notion is investigated and several possible combinations
are tested.
5.1 signature overlap – a sign for univer-
sal cancer signature
Elevated levels of single gene markers are often not only found in
a single type of cancer. This indicates that several cancers share the
same mechanism of survival, tumor growth and invasion. That can-
cers share the same mechanisms during development has been dis-
cussed before by Hanahan and Weinberg [79]. They discussed the
idea of common cancer signals and defined the Hallmarks of cancer
in which distinctive biological processes are responsible for tumor
growth, invasion and metastatic dissemination.
By investigating signatures obtained by NetRank, a significant sim-
ilarity between predictive genes was observed. In the following sec-
tion, the similarity of signatures of the original studies with signa-
tures obtained by NetRank is compared. Secondly, the effect of the
similarity on the prediction accuracy is assessed and finally the over-
lapping genes are analyzed regarding their Gene Ontology terms.
5.1.1 Signatures from original cancer studies do not overlap – even
for the same cancer type
The analysis of the signature similarity was performed on a bench-
mark dataset consisting of 25 literature derived datasets. The datasets
are quite diverse as they cover 13 different types of cancer including
breast and prostate cancer, leukemia and lymphoma. They differ in
the outcome variable (diagnosis, response to treatment, progression
67
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Figure 14: Signature simi-
larity between original pub-
lications as a) Jaccard Index
and b) -(log)((p-value)) of Jac-
card Index. A value of 0
(white) indicates no overlap
and 1 a strong overlap be-
tween the signatures. Only
the signatures of O’Donnell et
al. and Nanni (T) et al. show a
slight similarity as they share
7 genes. Note: No signature
was published for Nanni et al.
(D).
(a) Jaccard Index of original signatures
(b) −log(p− value) of Jaccard Index
or subtyping), the size of signatures (from 1 to 357 genes), and their
prediction accuracy (according to the authors from 60% to 100%), as
well as the methods employed. A summary of the datasets can be
found in Table 4.
For the comparison of signature similarity, the signatures as stated
in the original publications are taken. Note that, Nanni et al. did not
publish a signature for their diagnosis of prostate cancer dataset. The
pancreas cancer in-house dataset [196] is also not included.
No significant overlap for
original signatures
To investigate the overlap between signatures the pairwise similar-
ity of signatures represented as Jaccard Index is plotted against each
other. In Figure 14a, a value of 0 (white) indicates no overlap and
1 a strong overlap between the signatures. As expected Figure 14a
shows no significant overlap between the signatures published by the
authors. Even for studies investigating the same cancer and outcome
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variable, no overlapping genes exist. Exceptions are Nanni et al. (T)
[127] and O’Donnell et al. [132], which share seven transcription factor
out of 205 genes. We also computed p-values of Jaccard indices using
Fisher’s exact test, which shows the probability of an overlap between
the signatures by chance (see section 3.4). In Figure 14b a value of 0
(white) indicates that the signature could have occurred by chance.
The different colors in the diagonal arise due to the different sizes of
the signatures. The diagonal of Lee et al. [104] is almost white as the
signature consists of only one gene and could have clearly arisen by
chance. The figure also indicates the small overlap between Nanni et
al. (prostate cancer) and O’Donnell et al. (oral cavity).
This discovery supports the finding of Ein-Dor and co-workers as
they investigated two breast cancer signatures regarding their simi-
larity and found an overlap of almost zero [55].
5.1.2 Greedy techniques do not trigger signature similarity
One reason for the lack of overlap might be the variety of techniques
applied by the authors of the studies. None of the authors used ex-
actly the same methods or thresholds as the other authors. We there-
fore aimed at comparing the resulting signatures while applying the
same analysis to all datasets. Thus, we applied two standard greedy
techniques – t-test and foldchange – on each dataset. An explanation
of the methods can be found in section 3.5. These techniques do not
take into account any relationships between genes; they solemnly an-
alyze the relationship of the expression of a gene with the outcome
variable. Hence, genes chosen by these techniques often tend to corre-
late in their expression; therefore no information gain is achieved by
using several similar genes. Nevertheless, these standard techniques
are applied to the 25 datasets and the resulting signatures are com-
pared regarding their similarity.
No significant overlap for
signatures obtained by greedy
methods
As the Figure 15a and Figure 15b show, both t-test and foldchange
fail to construct stable signatures, with foldchange expressing small
similarities between certain signatures. This supports the finding of
Shi et al. [160, 161]. They showed in a comprehensive analysis that
foldchange results in more reproducible gene list than the t-test.
As conclusion neither the authors themselves nor the same analysis
methods are able to improve signature overlap to create stable pre-
dictive signatures. In the next section we investigate the signatures
obtained by NetRank regarding their similarity.
5.1.3 NetRank signatures do strongly overlap
To compute stable signatures, dependencies between genes have to
be considered and the data has to be aggregated. In former work, a
network-based outcome prediction approach – NetRank – was devel-
70 universal cancer signature
Figure 15: Signature simi-
larity of a) t-test and b) fold-
change represented as Jaccard
Index. A value of 0 (white) in-
dicates no overlap and 1 (red)
a strong overlap between the
signatures. Both t-test and
foldchange fail to construct
stable signatures, with fold-
change having a small simi-
larity between certain signa-
tures.
(a) Jaccard Index of t-test signatures
(b) Jaccard Index of foldchange signatures
oped that is able to cover these dependencies. In chapter 4 the algo-
rithm was applied on several types of cancer gene expression data
using 2 types of networks, a transcription factor network (Transfac
[119]) and a protein-protein interaction network (HPRD [146]). The
algorithm was not just having a better accuracy than random (13%
improvement), it also boosted the prediction accuracies compared to
classical methods like t-test and foldchange by 5%.
NetRank boosts signature
similarity
In order to investigate the overlap of the resulting signatures, the
pairwise similarity of signatures represented as Jaccard Index is again
plotted against each other. Figure 16 and Figure 17 show the similar-
ity of signatures obtained by NetRank applied on HPRD and Transfac
on the 25 datasets. The overlap is statistically significant and differ-
ent datasets covering either the same cancer type, as well as different
cancer types overlap well.
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Figure 16: The NetRank sig-
natures based on HPRD over-
lap nicely for the same type of
cancer as well as for different
cancer types. For example the
signatures of lung cancer of
Zhu et al. and Spira et al. over-
lap in all genes. HPRD-based
NetRank signatures share in
average 2 genes. In the fig-
ure a value of 0 (white) in-
dicates no overlap and 1 a
strong overlap between the
signatures.
Figure 17: The signature ob-
tained by NetRank based on
Transfac overlap strongly. All
signatures share in average
3.2 genes. Only for two (Spira
et al., Raponi et al.) out of
25 dataset there are no over-
lapping genes. A value of
0 (white) indicates no over-
lap and 1 a strong overlap be-
tween the signatures.
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Figure 18: The heatmap of
the −log(p − value) of the
Jaccard Index of Transfac
and HPRD-based NetRank
genes. Statistically significant
signature similarities (not by
chance) are represented by
higher values and red col-
ors. The signatures of Net-
Rank with HPRD and Trans-
fac are significantly overlap-
ping for many datasets.
For example the HPRD-based lung cancer signatures for the Zhu
et al. [206] and Spira et al. [168] datasets consist out of the same 10100% signature similarity for
two lung cancer datasets genes. A similar high overlap for leukemia can be observed in the
Transfac-based signature of Friedman et al. [65] and Frank et al. [64]
that overlap in nine out of ten genes. Moreover, signatures do overlap
which are not based on the same type of cancer. The signatures of
Nanni et al. [127] and Korkola et al. [96] share 6 out of 10 genes, which
might be surprising as they investigate prostate cancer and germ cell
cancer outcome, respectively.
For the NetRank signatures we also computed p-values of Jaccard
indices using Fisher’s exact test, which shows the probability of an
overlap between the signatures by chance. The −log(p − value) of
each pairwise similarity is plotted in Figure 18. The signatures of
NetRank using either physical interaction (HPRD) or regulatory in-
formation (Transfac) are significantly overlapping for many datasets.
Taking all these facts together, NetRank signatures based on Trans-
fac and HPRD share in average 3.2 and 2 genes, respectively. The
question arises whether this overlap is biologically meaningful, or
not. We hypothesize that the unique signature genes are cancer spe-
cific, whereas the overlapping genes represent general cancer signals.
The general principle of cancer development and growth has been
investigated since several decades. A literature search in GOPubmed1
yields 3 million publications annotated with the MESH term ’neo-
plasms’, making it to one of the mostly used disease terms. We there-
fore assume, that general cancer genes are well-studied and known
in literature. Hence, in the following section the most overlapping
genes are investigated regarding their biological relation and refer-
ence to cancer growth and development in literature.
1 http://gopubmed.org
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5.2 netrank genes are highly connected
and confirmed in literature
By using a network-based approach, signatures for 25 literature de-
rived datasets are created. For a detailed dataset description see Ta-
ble 4. While analyzing these datasets, a huge overlap between the
signatures was discovered. Table 11 and Table 12 show the signatures
obtained for each of the datasets applying NetRank on Transfac and
HPRD. In the Transfac-based signatures the specificity proteins 1 and
3 (SP1 and SP3) are selected in more than 20 and 18 signatures, respec-
tively. This is biologically reasonable as they are highly connected in
the network and regulate a huge amount of different proteins. A
similar picture can be drawn for the HPRD-based signatures. The fol-
lowing two sections describe in detail some of the highly connected
proteins and shed light on the biological processes involved.
5.2.1 Transfac-based NetRank genes
Transcription factors are especially suitable for cancer outcome pre-
diction. They act as signal transducers in signaling cascades by trans-
ferring information to genes by activating or repressing their expres-
sion. This key function renders transcription factors highly informa-
tive for signatures in malignant diseases. Table 13 shows the 13 genes
which occur more than 3 times in the Transfac-based NetRank signa-
tures. They are all master regulators with over 60 targets and as such
involved in many biological processes. At the same time, these genes
are known in literature as biomarkers for the majority of the 13 can-
cers of our datasets. Furthermore, all of them have been documented
independently in literature as possible cancer biomarkers for at least
two different cancers. The following paragraphs describe the biolog-
ical function of six transcription factor (SP1, SP3, JUN, FOS, NFKB1
and Rela).
SP1 and SP3 were selected in
more than 18 signatures
The specificity protein 1 (SP1) and 3 (SP3) are the most often cho-
sen proteins. They have a predictive power in 22 and 20 out of 25
datasets and each of them interact with or regulate 421 and 164 other
proteins, respectively. SP1 and SP3 play an important role in regu-
lating cell proliferation and have high levels of expression in several
cancer types, e.g., breast, pancreatic, colon and prostate cancer [1, 39,
81, 163]. Specifically, it was experimentally demonstrated that SP1
regulates proliferation and lipogenesis processes in colon, prostate,
and breast cancer cells [113]. Therefore, drugs decreasing the expres-
sion level of the SP family would also reduce the level of genes related
with cancer progression [38].
Jun and Fos form the AP1
complex
The Jun-like transcription factor (JUN) and the FOS protein has
been chosen as predictive 17 and 14 times, respectively. They interact
in the Transfac network with 154 and 138 different genes. JUN and
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Table 13: Top NetRank genes are part of many signatures, are transcrip-
tional master regulators, and are independently known in literature as can-
cer biomarkers (analysis based on 13 cancer types included in our analysis).
Gene Signature in # of targets # of 13 cancers
# of datasets in Transfac confirmed in literature
SP1 22 421 7
SP3 20 164 1
JUN 17 154 8
TP53 17 81 8
FOS 14 138 3
NFKB1 12 98 5
TFAP2A 9 76 6
CREB1 8 87 2
STAT1 7 61 4
EGR1 6 66 3
HNF4A 6 68 2
JUND 4 104 3
CEBPB 3 64 4
RELA 3 71 3
FOS families form the Activator protein 1 (AP-1) complex that con-
trols the expression of genes, regulating several cell processes, such
as proliferation, migration, survival, differentiation as well as apopto-
sis [112]. Overexpression of JUN was demonstrated in lung, leukemia,
glioblastoma, melanoma and prostate cancer cells [111, 135, 136, 148,
164]. However, FOS shows overexpression in prostate cancer cells
[136] and lower expression level in ovarian cancer [118]. The func-
tion of AP-1 changes based on its dimer composition (i.e., various
combinations of JUN and FOS family proteins) and cell content [6].
Although some AP-1 complexes (e.g., c-JUN and FOS) may activate
oncogenic target genes, some others (e.g., JUN and FRA1) may acti-
vate inhibitory pathways [159]. Drugs targeting JUN and FOS fam-
ily members consequently disrupt the AP-1 complex formation and
would provide an improvement in cancer treatments.
NFKB1 and Rela form the
NF-kB complex
The nuclear factor kappa-light-chain-enhancer of activated B cells
1 (NFKB1) has been selected in 12 out of 25 signatures as predictive.
It interacts with 98 other genes, including RELA, which is included
in 3 out of 25 signatures. NFKB1 forms together with RELA the NF-
kB complex that controls the expression of several genes regulating
immune responses, cell cycle, proliferation, and apoptosis [50]. The
promoting role of NF-kB in cancer progression has been extensively
investigated in the last decade. The studies proved that it is either
a tumor-suppressor or tumor-promoting oncogene based on muta-
tions occurring in the upstream region of NF-kB. A recent study has
shown that NF-kB has a tumor-suppressor function in ovarian cancer
[203]. High activation of NF-kB has been detected in hepatocellular
5.2 netrank genes are highly connected and confirmed in literature 77
carcinoma, melanoma, leukemia, and breast cancer [49, 72, 145, 173].
Another study proved that the activation of NF-kB is mostly related
with the inflammatory environment of tumor progression [92, 183].
Drugs disrupting function of NF-kB would lead to adverse effects for
normal tissues, hence upstream interactors of NF-kB could be more
effective drug targets for cancer treatments [92].
Transfac-based NetRank genes are highly interconnected
The Figure 19 shows the interconnectivity of 14 Transfac genes that
are selected more than 3 times as predictive in one of the 25 datasets.
As the figure shows, the genes are well interconnected, creating a
highly connected cluster of genes regulating each other. The only ex-
ception is the CCAAT/enhancer binding protein, beta (CEBPB) which
needs the matrix metallopeptidase 1 (MMP1) to be connected to the
subgraph. MMP1 is known to be involved in cancer metastasis and
is related to bladder [201] and oral cancer [57].
5.2.2 HPRD-based NetRank genes
Out of 25 signatures of NetRank based on the HPRD network, 23
genes got selected more than twice as predictive. These genes, their
connectivity as well as their literature occurrence are listed in Table 14.
These genes are generally highly connected to other genes in the
HPRD network. Some of them are involved in the transcription of
other genes or physically interact with master players of cancer de-
velopment. In the following paragraphs, the functions of seven genes
(PRKCA, SRC, TGFBR1, EGFR, ESR1, SMAD2, SMAD3), which are
well-known targets in different cancer therapies, are summarized.
Protein kinase C alpha
(PRKCA)
Protein kinase C alpha (PRKCA) is a member of the family of ser-
ine/threonine protein kinases and it regulates cardiac contractility,
atherogenesis, and cancer [95]. PRKCA is activated by the tumor
promoter phorbol ester [32] and its function is related with cell pro-
liferation, apoptosis and cell motility in cancer. It is over- and under-
expressed in different cancer types [95], hence it became a target for
various cancer treatments. However several drugs targeting PRKCA
activity have not provided a new adequate cancer therapy yet [121].
Proto-oncogene tyrosine-protein
kinase Src
Proto-oncogene tyrosine-protein kinase Src (SRC) is discovered as
first human oncogene and encodes a tyrosine kinase protein that reg-
ulates differentiation, survival, angiogenesis and motility in cancer.
Significant activity of SRC was detected in colon, breast, lung, pan-
creatic and prostate cancers [194]. SRC interacts with several kinases,
e.g. EGFR, VEGFR, PDGFR, CSF1R, HER2, HER3 and IGF1R. There
are many ongoing studies and clinical trials that aim to inhibit activ-
ity of SRC in various cancers [147]. Due to synergistic effect between
SRC and EGFR in tumor development [88, 114], new cancer therapies
should target the inhibition of both genes concurrently [194].
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Figure 19: The figure shows
the connectivity of the most
chosen Transfac genes. The
genes are generally well in-
terconnected. Only one inter-
mediate gene is needed (grey
circle; MMP1) to connect all
genes with each other. The
color indicates the number of
occurrences of a gene in the
resulting signatures.
TFAP2A
SP3 MMP1
FOS
JUN
JUND
TP53
NFKB1
CEBPB
HNF4ASTAT1 CREB1
SP1
RELA
EGR1
Frequency 
in signature:
0                           22
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Table 14: Top NetRank genes are part of many signatures, are indepen-
dently known in literature as cancer biomarkers (analysis based on 13 can-
cer types included in our analysis). All listed genes occur more than once
in the results.
Gene Signature in # of targets # of 13 cancers
# of datasets in HPRD confirmed in literature
ATXN1 20 159 2
EWSR1 17 117 1
YWHAG 12 247 1
PRKCA 10 172 6
PRKACA 10 145 3
SMAD2 8 166 4
CREBBP 8 198 4
SMAD3 7 182 4
NDRG1 7 61 5
CSNK2A1 7 168 5
SRC 6 208 7
ATN1 5 88 -
FDCSP 3 0 -
CDK1 3 119 5
IGJ 2 2 1
MUC4 2 2 3
SKIL 2 73 -
SVIL 2 63 1
TGFBR1 2 154 1
CR2 2 10 3
EGFR 2 161 6
EP300 2 209 4
ESR1 2 188 4
Transforming growth factor, beta
receptor I (TGFBR1) induces
SMAD2 and SMAD3
Transforming growth factor, beta receptor I (TGFBR1) is a member
of the transforming growth factor beta family of cytokines that have
roles in proliferation, differentiation, adhesion, migration and apopto-
sis. SMAD2 and SMAD3 are signal transducer proteins that regulate
several processes such as proliferation, differentiation and apoptosis.
Activated TGFBR1 induces SMAD signaling by phosphorylation of
SMAD2 and SMAD3, then SMAD4 translocates into the nucleus and
starts transcription of target genes. Therefore, the SMAD pathway is
important for the growth inhibitory action of TGFBR1 [43]. Loss of ex-
pression of TGFBR1 is frequently observed in gastric, colon, and blad-
der cancer [107]. Mutations on SMAD2 (frequent) and SMAD3 (less
frequent) are detected in colon cancer [60]. Therapy options of TGF-β
signaling could be either the inhibition of TGFBR1 by small molecules
or disrupting SMAD family interactions by peptide aptamers [43].
Epidermal growth factor
receptor (EGFR)
The epidermal growth factor receptor (EGFR) is a cell-surface re-
ceptor that has important roles in proliferation, cell cycle and migra-
tion processes [204]. Mutation or overexpression of this receptor may
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cause the development of lung, colon, breast, ovarian, glioblastoma
and pancreatic cancers. Therefore EGFR is an important target for
several cancer therapies. It has also a high prognostic power for vari-
ous cancer types [14, 33, 130].
Estrogen receptor 1 (ESR1) ESR1 encodes the estrogen receptor 1 that is activated by the es-
trogen hormone. The activated receptor translocates into the nucleus
and initiates transcription of different genes. This receptor is active
in round 60-70% of breast cancer tumors [108]. Hence, several breast
cancer therapies try to decrease estrogen levels or to interrupt the es-
trogen receptor signaling pathway. Expression of ESR1 could be used
as biomarker to predict survival time of ovarian and endometrial can-
cer patients [29].
HPRD-based NetRank genes are well interconnected
The Figure 20 shows the in-between connectivity of the top 23 HPRD
genes. These genes got selected at least 3 times as predictive in one
of the 25 datasets. As the figure shows, the proteins are well inter-
connected with each other. In contrast to the Transfac genes, there
is a core of proteins that are more connected to each other and some
peripheral proteins. The peripheral genes are IGJ, ATXN1 and MUC4.
The proteins immunoglobin J (IgJ) and ataxin 1 (ATXN1) are con-
nected over FYN – an oncogene related to SRC, FGR, YES – to the core
proteins. In addition needs IgJ one more connector, which is CD79A
– an immunoglobulin-associated molecule, also known as IgA. Mucin
4 (MUC4), a cell surface associated protein, is the most distant gene
and needs 3 intermediate proteins (ERBB2, CAV1, ABL1) to be con-
nected to the core proteins.
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5.3 hallmarks of cancer
In the previous section the similarity of signatures obtained by the
authors, greedy methods and NetRank was investigated. We showed,
that the original as well as the t-test and foldchange signatures do not
overlap, whereas signatures retrieved by NetRank display a strong
overlap. The overlapping genes are highly connected in Transfac and
HPRD, respectively. Literature analysis showed, that these genes are
related to cancer and have been mentioned already as biomarker for
outcome prediction.
In the following section the overlapping Transfac and HPRD genes
are analyzed regarding the ’Hallmarks’ of cancer [79, 80].
Hallmarks of cancer summarize
the underlying principles of
cancer development
Hanahan and Weinberg claim that the complexity of cancer can
be reduced to a small number of underlying principles [79]. They
argue that all cancers share eight common ‘Hallmarks’, which gov-
ern the transformation from normal cells into cancer cells. Assuming
these signature genes could form a possible Universal Cancer Sig-
nature, they should be involved in at least some of the Hallmarks
suggested. We mapped the Gene Ontology annotations to the differ-
ent Hallmarks of Cancer and could find associations to the following
8 Hallmarks2:
1. cancer cells stimulate their own growth;
2. they resist inhibitory signals that might otherwise stop
their growth;
3. they resist their own programmed cell death (apoptosis);
4. they stimulate the growth of blood vessels to supply nutri-
ents to tumors (angiogenesis);
5. they can multiply forever;
6. they invade local tissue and spread to distant sites (metas-
tasis);
7. they are able to evade immune destruction;
8. they are able to reprogram their glucose metabolism.
The first six Hallmarks are general principles already published in
2000 [80]. The emerging Hallmarks – the evasion of the immune sys-
tem as well as the reprogramming of the glucose metabolism – have
been published recently. In preclinical studies it has been shown, thatAn active immune system
prevents cancer an active immune system continuously recognizes and eliminates the
majority of cancer cells before they establish themselves and form a
2 Images taken from original publication
5.3 hallmarks of cancer 83
Table 15: The Hallmarks of cancer are well represented by the signature
genes based on the Transfac network. The Hallmarks of metabolic repro-
gramming and metastasis formation are sparsely covered by only HNF4A,
whereas the Hallmark of resistance to inhibitory signals is covered by eight
out of the 14 proteins and the remaining Hallmarks are at least represented
by three genes. Except JunD – which only represents the Hallmark of blood
vessel growth – all genes cover more than one Hallmark.
Gene
SP1 ✓ ✓ ✓
SP3 ✓
JUN ✓ ✓ ✓ ✓
TP53 ✓ ✓ ✓ ✓ ✓
FOS ✓ ✓
NFKB1 ✓ ✓ ✓
TFAP2A ✓
CREB1 ✓
STAT1 ✓ ✓
EGR1 ✓ ✓
HNF4A ✓ ✓ ✓ ✓ ✓
JUND ✓
CEBPB ✓ ✓
RELA ✓ ✓ ✓
tumor mass. Clinical examples also support this finding and demon-
strate that colorectal and ovarian cancer patients with an increased
immune response have a better prognosis than patients with a re-
duced immune response [79, 182].
Cancer cells are able to perform
aerobic glycolysis
Due to the Warburg effect, cancer cells are able to reprogram their
glucose metabolism and convert high amounts of glucose to lactate
even in the presence of oxygen (aerobic glycolysis) [179]. This exhibits
a sharp contrast to normal cells, which show a decrease of glucose
uptake and inhibition of lactate production under aerobic conditions.
A recent study found in addition, that glucose-starved colon cancer
cells tend to be more aggressive [115].
NetRank genes cover Hallmarks of Cancer
Table 15 and Table 16 show the Transfac and HPRD-based genes
mapped to Hanahan and Weinberg’s Hallmarks of cancer. The rela-
tionship between the Hallmarks and a certain gene was assessed via
Gene-Ontology terms. Gene-Ontology terms were extracted using
the Database for Annotation, Visualization and Integrated Discovery
(DAVID) [82]. Afterwards the Ontology-terms were annotated to one
of the Hallmarks.
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Table 16: The Hallmarks of cancer are covered by the signature genes based
on the HPRD network, The majority of Hallmarks are represented by at
least 3 proteins. The vast majority of genes caps at least 2 Hallmarks. Simi-
lar to Transfac, the Hallmark of metabolic reprogramming is sparsely repre-
sented only by the cAMP – dependent protein kinase catalytic subunit alpha
(PRKACA).
Gene
ATXN1 ✓
EWSR1 ✓
YWHAG ✓
PRKCA ✓ ✓ ✓ ✓
PRKACA ✓ ✓ ✓
SMAD2 ✓
CREBBP ✓
SMAD3 ✓ ✓ ✓ ✓ ✓ ✓
NDRG1 ✓
CSNK2A1 ✓ ✓
SRC ✓
ATN1 ✓
FDCSP ✓
CDK1 ✓ ✓
IGJ ✓
MUC4 ✓
SKIL ✓
SVIL ✓
TGFBR1 ✓ ✓ ✓ ✓ ✓
CR2 ✓
EGFR ✓ ✓ ✓ ✓
EP300 ✓ ✓
ESR1 ✓
In the case of Transfac-based signature genes, each hallmark is cov-
ered by at least one signature gene. The Hallmarks of metabolic re-
Transfac and HPRD-based
NetRank genes cover Hallmarks
of cancer
programming and metastasis formation are sparsely covered by only
one protein - Hepatocyte nuclear factor 4 alpha (HNF4A). All other
Hallmarks are represented by at least three genes, with the resistance
to inhibitory signals being covered by eight out of the 14 proteins. In
addition, all genes, except JunD, represent more than one Hallmark.
It was only possible to connect JunD to the Hallmark of blood ves-
sel growth. Specifically, the most frequently observed Hallmarks are
resisting to inhibitory signals, apoptosis and angiogenesis.
A similar picture can be drawn for genes obtained on the HPRD
network (see Table 16). Again the Hallmark of metabolic reprogram-
ming is sparsely represented only by the cAMP-dependent protein
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kinase catalytic subunit alpha (PRKACA). The remaining Hallmarks
are covered by at least 3 proteins and the vast majority of genes cap
at least 2 Hallmarks.
5.4 testing possible universal cancer sig-
natures
In the previous section the relationship between the NetRank signa-
tures and the Hallmarks of cancer have been discussed. Having these
genes covering all Hallmarks of cancer, it might be possible to gener-
ate a Universal Cancer Signature able to predict any kind of cancer.
This idea is reviewed in the following section.
5.4.1 Random signature as Universal Cancer Signature?
Venet and co-workers claim that 90% of all random signatures with
more than 100 genes are a similar good predictor as any constructed
signature [188]. This statement is tested on the in-house pancreas can-
cer dataset of Winter et al. [196]. Therefore, 1000 signatures of length
101 genes are created and during cross-validation it is measured how
often the accuracy is better than the original NetRank accuracy of
72%.
90% of random signatures are
NOT better than constructed
signatures
results The random signatures where never better than the con-
structed signatures, nevertheless approaching the accuracy with a dif-
ference of 5% (68%) in 5 out of the 1000 cases. The overall prediction
accuracy of the random signatures was 55.6%, which is an improve-
ment over the random signatures of length 10 (52%). But this results
indicates that 90% of random signatures with more than 100 genes
are not better than constructed signatures, disproving the point of
Venet and co-workers.
After all, following this study, maximal 10275 combinations have
to be tested to discover a Universal Cancer Signature with 100 out
of roughly 22.000 human genes. This is computationally demanding
and not easily feasible at this point as testing the 1000 combinations
for the pancreas cancer dataset in a Monte Carlo cross-validation pro-
cedure took already 200 CPU h. Therefore, selective testing is in-
evitable.
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5.4.2 Combination of the most selected genes
Investigating signatures obtained by NetRank – based on Transfac
and HPRD – a significant similarity between the different signatures
could be observed and 37 genes have been chosen more at least three
times as predictor. This limits the search space from roughly 22,000
human genes to 37. Nevertheless choosing 10 out of 37 still leads
to 109 comparisons, assuming the best Universal Cancer Signature
consist out of 10 genes. To test all possible combinations, 237 compar-
isons have to be computed. This is computationally demanding and
currently also not easily feasible.
5.4.3 Baseline accuracy - Top 10 highly connected transcription
factors
To assess the performance of any signature, a baseline accuracy is
needed. Highly connected genes are often well known cancer genes.
As discussed before, most cancer types arise due to mutations in regu-
latory elements, creating alterations in transcription factor expression,
which finally leads to unregulated cell growth and differentiation. In
addition, transcription factors have been discussed as one of the main
sources of cancer development [128] as well as suggested as targets
for cancer therapy [47].
Following this, the investigation focuses on the most highly con-
nected genes in the Transfac network (TF10) and chooses them as
the baseline signature. The TF10 signature consisted of the following
genes: TP53, NFKB1, RELA, JUN, SP1, STAT1, CREB1, HNF4A, FOS,
TFAP2A.
Highly connected Transfac genes
not useful as a Universal Cancer
Signature
Table 17 column TF10 shows the accuracy of these signature on
the benchmark dataset. It is better than randomly selected signatures
in 12 out of 25 datasets, resulting in no average improvement. In
comparison to the classical methods of t-test and foldchange, the TF10
is better in seven out of 25 datasets, nevertheless the resulting overall
performance was 5% worse.
5.4.4 Top 10 most often used NetRank genes
NetRank chooses genes based on the gene expression and the connec-
tivity of that gene in a network. Out of the 37 genes the top 10 most
often used Transfac-based NetRank genes (NR10) were combined into
a possible Universal Cancer Signature and tested on the 25 datasets.
The NR10 signature consists of the following genes: SP1, SP3, JUN,
TP53, FOS, NFKB1, TFAP2A, CREB1, STAT1, EGR1.
Table 17 column NR10 shows the accuracy of these signature on
the benchmark dataset. It is better than random predictors in 13
out of 25 datasets, resulting in an average improvement of 3%. In
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Table 17: Prediction accuracies achieved by the probable Universal Cancer
signatures of NR10 and TF10 in comparison to random predictors (Rand),
classical methods (FC and TT) and original NetRank signatures (NR).
Author FC TT NR NR10 TF10 Rand
Jones et al. [90] 86 85 89 82 77 79
O’Donnell et al. [132] 66 78 81 75 75 75
van de Vijver et al. [191] 61 58 67 - - 62
Spira et al. [168] 66 67 71 65 62 65
Lee et al. [104] 70 69 75 55 57 56
Steidl et al. [170] 72 75 74 69 69 70
Bhojwani et al. [20]
T 64 58 64 42 39 51
P 67 64 71 62 59 54
Bogunovic et al. [22] 53 63 67 63 69 56
Friedman et al. [65] 52 60 56 50 52 53
Raponi et al. [149] 59 55 62 50 50 54
Wang et al. [192] 66 65 69 64 65 66
Korkola et al. [96] 67 64 70 69 69 67
Landemaine et al. [100] 95 90 100 67 67 67
Nanni et al. [127]
D 89 96 100 90 89 90
T 55 62 71 44 30 31
Iqbal et al. [86] 76 77 82 73 70 67
Fernandez et al. [59] 78 67 81 46 43 44
Frank et al. [64] 70 67 73 66 71 66
Smith et al. [166] 68 57 72 60 60 62
Lenzet al. [106] 60 59 64 61 60 60
Mok et al. [122] 60 54 65 66 54 65
Dressman et al. [52] 51 46 60 57 57 43
Murat et al. [125] 49 46 59 55 54 48
Zhu et al. [206] 50 46 56 57 58 50
Accuracy %:
30-34 35-40 41-45 45-50 51-55 56-60 61-65
66-70 71-75 76-80 81-85 86-90 91-95 96-100
comparison to the classical methods, the NR10 is better in 10 out of
25 datasets, nevertheless the resulting overall performance was 7%
worse. Note that the difference between TF10 and NR10 is quite low
as they overlap in eight out of ten genes.
Most often chosen Transfac
genes not useful as a Universal
Cancer Signature
As the overall accuracy is not better than the individual signatures,
the NetRank based NR10 fails to reliably predict different cancer out-
come datasets.
Even though covering all Hallmarks of cancer, neither the NR10
nor the baseline TF10 signature is suitable as a Universal Cancer Sig-
nature.
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5.4.5 Combination of HPRD and Transfac genes
Another possibility could be a combination of the most often chosen
Transfac and HPRD genes. As transcription factors are especially ap-
propriate for cancer outcome prediction, all Transfac genes are taken
and combined them with the HPRD genes, which were at least se-
lected 6 times as predictive in the 25 datasets. Table 18 describes the
resulting signature (COMB10) in detail.
Table 19 shows the predictive results of each part of the signatures
and the combination of the genes. TF indicates the accuracy obtained
by using 14 Transfac genes and HPRD are the remaining 9 genes from
Table 18. The NetRank column shows the accuracy obtained by the
original NetRank signatures build on Transfac.
Combination of top genes not
useful as a Universal Cancer
Signature
The dataset of van de Vijver et al. [191] was excluded, as this data-
set does not contain gene expression information for all genes in
COMB10. As the table shows, in only five out of the remaining 24
datasets, COMB10 achieved a better accuracy then using Transfac or
HPRD signatures alone (bold numbers). In another five datasets the
results of the COMB10 signature are comparable to the original Net-
Rank signatures. In the special case of Mok et al. [122] the accuracy
achieved by the combination of highly connected HPRD and Transfac
genes is better than the original NetRank signature (69% versus 65%).
For this comparison, several machine learning approaches are ap-
plied, but for sake of comparability only accuracies obtained with
SVM are shown. Again the k-nearest neighbor method achieved the
best prediction accuracy with 63%, 65%, 63% accuracy in Transfac,
HPRD and combined, respectively. In contrast, the Support Vector
Machines only reached an accuracy of 61%, 61% and 62%. Neverthe-
less the differences are subtle, thus the performance of the different
machine learning methods are comparable to each other. In small
datasets with less than 100 patients, differences in prediction accu-
racy of 1% lead to the not significant correct prediction of one extra
patient.
As summary, the individual NetRank signatures are still better than
a combination of the most important Transfac and HPRD genes.
5.4.6 Individual NetRank Signatures
As testing all possible combination of the NetRank genes is not fea-
sible and also NR10, TF10 or COMB10 failed to reliably predict the
outcome, maybe a NetRank signature obtained on the benchmark
dataset could be a better predictor for other datasets. Therefore, sig-
natures obtained on each dataset were tested on the remaining 24
datasets. The following analysis focuses on Transfac-based NetRank
signatures.
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Table 18: Transcription factors are especially appropriate for cancer out-
come prediction, therefore we took all Transfac genes from Table 13 and
combined them with the HPRD genes, that were at least selected 6 times as
predictive in the benchmark dataset. The table summaries these signature
genes (COMB10).
GeneID Symbol Description HPRD TF
6310 ATXN1 ataxin 1 ✓
1051 CEBPB CCAAT/enhancer binding
protein (C/EBP), beta
✓
1385 CREB1 cAMP responsive element
binding protein 1
✓
1387 CREBBP CREB binding protein ✓
1457 CSNK2A1 casein kinase 2, alpha 1 ✓
1958 EGR1 early growth response 1 ✓
2130 EWSR1 EWS RNA-binding protein 1 ✓
2353 FOS FBJ murine osteosarcoma viral
oncogene homolog
✓
3172 HNF4A hepatocyte nuclear factor 4,
alpha
✓
3725 JUN jun proto-oncogene ✓
3727 JUND jun D proto-oncogene ✓
10397 NDRG1 N-myc downstream regulated 1 ✓
4790 NFKB1 nuclear factor of kappa light
polypeptide gene enhancer in
B-cells 1
✓
5566 PRKACA protein kinase,
cAMP-dependent, catalytic,
alpha
✓
5578 PRKCA protein kinase C, alpha ✓
5970 RELA v-rel avian
reticuloendotheliosis viral
oncogene homolog A
✓
4087 SMAD2 SMAD family member 2 ✓
4088 SMAD3 SMAD family member 3 ✓
6667 SP1 Sp1 transcription factor ✓
6670 SP3 Sp3 transcription factor ✓
6714 SRC v-src avian sarcoma
(Schmidt-Ruppin A-2) viral
oncogene homolog
✓
6772 STAT1 signal transducer and activator
of transcription 1, 91kDa
✓
7020 TFAP2A transcription factor AP-2 alpha ✓
7157 TP53 tumor protein p53 ✓
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Table 19: Results of a combined signature - TF are genes from Transfac,
HPRD are genes from HPRD and combined indicates accuracy by combin-
ing both signatures (COMB10). The NetRank column gives the accuracy ob-
tained by NetRank based on Transfac. In bold we marked, when COMB10
outperforms the TF and HPRD-based signatures. In only five out of the re-
maining 24 datasets, COMB10 achieved a better accuracy than using Trans-
fac or HPRD signatures alone.
Dataset TF HPRD COMB10 NetRank
Jones et al. [90] 83 81 83 97
Spira et al. [168] 62 67 69 69
Lee et al. [104] 55 56 57 76
Steidl et al. [170] 71 68 70 74
Bhojwani et al. [20]
T 43 55 49 64
P 60 63 60 72
Bogunovic et al. [22] 63 57 59 70
Raponi et al. [149] 46 56 58 59
Wang et al. [192] 65 67 67 67
Korkola et al. [96] 69 68 71 71
O’Donnell et al. [132] 75 75 75 81
Friedman et al. [65] 56 54 55 55
Landemaine et al. [100] 67 67 67 99
Nanni et al. [127]
D 88 86 89 99
T 36 31 36 70
Iqbal et al. [86] 71 68 69 82
Fernandez et al. [59] 42 44 44 81
Frank et al. [64] 70 67 66 75
Smith et al. [166] 60 62 60 71
Lenz et al. [106] 61 59 63 65
Mok et al. [122] 55 70 69 65
Dressman et al. [52] 59 40 42 64
Murat et al. [125] 50 44 49 59
Zhu et al. [206] 54 54 54 58
Accuracy %:
30-34 35-40 41-45 45-50 51-55 56-60 61-65
66-70 71-75 76-80 81-85 86-90 91-95 96-100
The results can be found in Figure 21, where the x-axis shows the
datasets and the y-axis shows the signatures sorted by best average
accuracy. White boxes indicate accuracies worse than 50% (random
guess). As the figure shows, nearly all signatures are better than
random. Caution has to be taken in the case of van’t Veer et al. [185],
as the dataset does not provide information about all transcription
factors used.
Signature obtained from
Fernandez et al. dataset shows
best performance
Figure 21 is sorted by average accuracy, indicating the best signa-
ture as the first row, which is the NetRank signature created on the
data of Fernandez et al. for lymphoma subtyping [59]. The signa-
ture is composed of the following genes: SP1, SP3, TP53, HDGFRP3,
RNGTT, FOS, HNF4A, JUN, PON2, FARP1. This signature appears to
consist of general cancer proteins: SP1, SP3, TP53, FOS, HNF4A, JUN
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Figure 21: Accuracy of in-
dividual NetRank signatures
against all datasets. The x-
axis shows the datasets and
the y-axis shows the NetRank
signatures sorted by best aver-
age signature. White boxes in-
dicate an accuracy worse than
50%. Signatures perform bet-
ter than random (only a few
white boxes) and the NetRank
signature obtained on the Fer-
nàndez et al. performs best on
all datasets. Some datasets
(Nanni D, Jones and Steidl)
are solved well by all signa-
tures.
and specific proteins: HDGFRP3, RNGTT, PON2, FARP1, which – in ad-
dition – cover all Hallmarks of cancer. The signature achieves on
average a prediction accuracy of 62%, ranging across many different
cancer types. In 11 out of 25 cases, this lymphoma signature outper-
forms the classical methods, creating cancer-specific signatures.
The diagonal represents the original NetRank accuracy, obtained
and tested on the same dataset. Due to the significant similarity be-
tween predictive signatures, accuracies on the diagonal are similar to
the rest of the comparisons.
Some datasets are difficult to
capture
Furthermore, there are datasets which are easier to predict than
others. The signal in the Nanni et al. diagnosis dataset [127] is strong
enough to be easily captured by all signatures. In contrast, some
datasets e.g. Mok et al. [122] and Nanni et al. (T) seem to be difficult
to predict, as our method obtains average accuracies below 50%.
Although these results show a better prediction than a random
guess, there is still little evidence for a generic Universal Cancer Sig-
nature. Nevertheless, it appears that a cancer-specific combination
of general master regulators achieves the best results for all cancer
types.
5.4.7 Influence of general and specific cancer markers
As no Universal Cancer Signature was detected so far, we investi-
gated the notion of having signatures with general and specific can-
cer genes. This analysis was limited to Transfac-based NetRank sig-
natures.
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Table 20: Influence of general (Hub) and specific genes (noHub) on the
prediction results. The Hub column indicates the prediction accuracy of
the general cancer genes. These genes have more than 40 connections in the
Transfac network. The NetRank column shows the accuracy obtained by the
original NetRank signatures build on Transfac. For the majority of datasets,
the combination of general and specific cancer genes lead to an improved
prediction accuracy compared to using hub or non-hub genes alone.
Dataset Hubs noHubs NetRank
Bhojwani et al. [20]
T 60 61 64
P 68 72 72
Fernandez et al. [59] 60 83 81
Iqbal et al. [86] 71 79 82
Jones et al. [90] 67 92 97
Korkola et al. [96] 71 69 71
Lee et al. [104] 64 68 76
Lenz et al. [106] 63 59 65
Mok et al. [122] 55 63 65
Murat et al. [125] 58 64 59
O’Donnell et al. [132] 77 80 81
Smith et al. [166] 60 70 71
Steidl et al. [170] 70 72 74
Wang et al. [192] 66 68 67
Accuracy %:
30-34 35-40 41-45 45-50 51-55 56-60 61-65
66-70 71-75 76-80 81-85 86-90 91-95 96-100
Hub genes are defined as genes with more than 40 connections in the Trans-
fac network and include the following genes:
TP53 NFKB1 STAT3 CDKN1A MYC RELA FOS
STAT1 CREB1 HNF4A CEBPA EGR1 CEBPB JUNB
IRF1 YY1 GATA1 TFAP2A SP3 ATF2 ETS1
JUND GABPA FOSB JUN SP1 USF1
In order to see the influence of these two types of genes on the
prediction result, we decided to return to the individual signatures
and use solely genes for prediction that are in our definition either
general or specific cancer genes. In this study general cancer genes
are defined as genes having more than 40 connections in the Trans-
fac network. Table 20 (bottom) shows genes that are, based on our
definition, general cancer genes.
Not all signatures contain – following our definition – general and
specific genes. Eleven out of 25 datasets do not fulfill the criteria,
whereupon three datasets only contain specific genes (Raponi et al.,
Spira et al., van de Vijver et al.) and the remaining eight just contain
hub genes (Bogunovic et al., Dressmann et al., Frank et al., Friedman
et al., Landemaine et al., Nanni et al., Zhu et al.). The results might
be slightly overestimated as the signatures were obtained using the
entire dataset. During this analysis parts of the signature were re-
used, which might lead to overestimation of the predictive power.
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Table 21: Overlap of the anti-profile signature of Bravo et al. [27] with
the signature genes obtained with NetRank based on Transfac (NR-TF) and
HPRD (NR-HPRD).
Overlap anti-profile with
Author Cancer Var. NR-HPRD NR-TF
Bhojwani et al. [20] Leukemia
P MUC4 -
T
MUC4,
POU4F1,
PHACTR3
MUC4,
POU4F1,
PHACTR3
Fernandez et al. [59] Lymphoma S SOX11 -
Jones et al. [90] Renal cell S - USH1C
Landemaine et al. [100] Breast P MAGEA11 -
Raponi et al. [149] Lung P -
KRT6A,
KRT5
Smith et al. [166] Colon P MAGEA6
MAGEA6,
WDR72
Steidl et al. [170] Lung T TMSB15A -
Wang et al. [192] Breast P - MMP1
Table 20 shows the results of the separated signatures in compari-
son to the original results. The Hubs column indicates the prediction
accuracy of the general cancer genes. These genes have more than
40 connections in the Transfac network. The NetRank column shows
the accuracy obtained by the original NetRank signatures build on
Transfac.
For the majority of datasets, the combination of general and spe-
cific cancer genes lead to an improved prediction accuracy compared
to using hub or non-hub genes alone. In the case of Fernandez et al.
[59] and Murat et al. [125] the non-hub gene signature outperforms
the NetRank signature by 2% and 5%, which might be due to the per-
formance overestimation. In the remaining cases NetRank performs
similar or better than the general or specific cancer gene signatures.
The results indicate that there is no Universal Cancer Signature,
but that a combination of cancer-specific genes and general master
regulators achieves the best results for all cancer types.
universal cancer signature of bravo et al. In a recent publi-
cation, Bravo and co-workers present a statistical technique that iden-
tifies genes showing normal variation in healthy samples, but hyper-
variability across tumor samples [27]. In the first step they created
a predictor consisting of 542 genes for colon cancer and achieved an
AUC of 0.89 on 30 patients. Han et al. developed a signature using
the same patient samples and achieved with only 5 genes a similar
result (AUC 0.88).
In a second step Bravo et al. developed an anti-profile Universal
Cancer predictor consisting of 716 genes using 688 healthy and 4.138
cancer samples from 59 types. As they did not have enough samples
for each cancer type, no accuracy for their signature is stated.
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These two signatures are compared with the NetRank signatures
NetRank genes overlap with
anti-profile Universal Cancer
predictor
and common genes in NetRank signatures based on HPRD and Trans-
fac are observed with the colon cancer signature and the anti-profile
universal predictor. Our benchmark dataset includes one colon can-
cer dataset, which overlaps in two and three genes for HPRD and
Transfac, respectively. These genes are MAGEA6, SPP1 and WDR72.
Twelve out of the 716 genes of the anti-profile signature are found
in the 25 NetRank signatures. Table 21 shows the datasets which con-
tain genes found in the anti-profile signature. Interestingly, in the sig-
nature of the leukemia dataset of Bhojwani et al. [20] three out of ten
genes are found in the anti-profile signature. In addition, the genes
MUC4 and MMP1 are found in the highly connected HPRD and Transfac
cluster (see Figure 20 and Figure 19). The matrix metallopeptidase
(MMP1) is in the Transfac network an interconnector for CEBPB to the
remaining Transfac genes, whereas MUC4 is found in the periphery of
the HPRD cluster.
This result proves that these overlapping genes could be responsi-
ble for both initiation and development of specific cancer types.
5.5 conclusion
When analyzing gene expression data with the purpose of finding
clinical relevant biomarkers for cancer outcome prediction, genes se-
lected for prediction should not just work on the initial dataset but
also on other patient data. While comparing breast cancer progres-
sion signatures published by van’t Veer et al. [185] and Wang et al.
[192] no significant overlap between these two signatures was found.
The authors concluded that many equally predictive lists could have
been produced [55]. If signatures have genes in common, these over-
lapping genes should cover general signals in cancer development
and accordingly overlap with the Hallmarks of cancer. These Hall-
marks, introduced by Hanahan and Weinberg in 2000, reduce cancer
development and growths to a small number of underlying principles
[80].
No similarity between the
published signatures of the
benchmark dataset
We continued along these lines and compared signatures obtained
from 25 publications regarding their similarity. We show that there
is no significant overlap between these signatures. Even for studies
investigating the same cancer and outcome variable, no overlapping
genes exist, proving the point of Ein-Dor and co-workers [55].
No overlap between signatures
obtained by greedy methods
This lack of similarity might be due to different statistical method-
ologies used during signature development. To investigate the effect
of the methods on the resulting predictive signatures, we applied two
standard methods t-test and foldchange on all datasets. We show that
both techniques were not able to construct stable signatures as no sig-
nificant overlap between signatures was visible.
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Finally, we investigated whether network-based analysis of gene
expression data is able to improve the overlap between predictive sig-
natures. We therefore analyzed the similarity of signatures obtained Network-based methods trigger
signatures overlapby NetRank – a PageRank derivative – that combines the correlation
of expression level of a gene with the outcome variable of the pa-
tient by using a network of known gene-gene relationships. NetRank
was applied on two types of networks – a protein-protein interaction
network (HPRD) and a transcription factor-target network (Transfac).
The resulting signatures share in average 2 and 3.2 genes, respectively.
Overlapping genes are known
cancer biomarker and cover
Hallmarks of cancer
The overlapping genes are highly connected and a literature anal-
ysis showed, that these genes are related to cancer and have been
mentioned already as biomarker for outcome prediction. We inves-
tigated the genes regarding the Hallmarks of cancer and show that
all Hallmarks are covered by the overlapping genes. We in particu-
lar single out six transcription factor and seven proteins and discuss
their specific role in cancer progression.
No general Universal Cancer
Signature could be identified
Having this set of overlapping genes, we tried to identify a Univer-
sal Cancer Signatures that is able to predict cancer development and
progression in a variety of different cancer types. So far, no Universal
Cancer Signature could be identified.
A combination of hub and
no-hub genes approximates a
Universal Cancer Signature
Nevertheless, we investigated the signatures regarding general and
cancer specific genes and concluded that a combination of both achie-
ves the best result for all cancer types.

6 C LO U D - B A S E D B I O M A R K E R
D I S C O V E R Y
As NetRank offers a great value for cancer outcome prediction, I
wanted to make the algorithm accessible to other researchers. Never-
theless, running NetRank on large gene expression datasets requires
appropriate computational resources as well as the adjustment of the
algorithm and a specialized data management.
Cloud services offer such resources, but security concerns rise
when valuable research data is transferred to a public Cloud. Such a
Cloud service could provide physicians a valuable tool for supporting
the selection of treatment options, when it is possible to use the gene
expression data obtained from the patient’s tissue sample. However,
patient data is confidential and thus has to be secured appropriately
while being processed in the Cloud.
6.1 introduction to secure cloud comput-
ing
The use of High-performance computing (HPC) systems for biomedi-
cal research has a long history [98] and is in the transition to Cloud
computing (e.g. Cloud storage systems for DNA sequencing [123]) –
going away from in-house solutions. However, this brings new prob-
lems such as vendor lock-in and a potentially untrusted environment.
Contrary to the increased economic efficiency, flexibility and all the
other advantages of the Cloud computing, there are still a few major
drawbacks related to privacy issues and possible loss, which prevent
broad adoption.
There are many proposals on how to enhance data privacy in the
public and hybrid Cloud computing scenario [150]. However, these
techniques possess advantages and disadvantages that need to be
considered before application. Some methods like homomorphic en-
cryption provide a high security level, but data transformation is ex-
tremely time consuming, thus increasing execution time dramatically.
In contrast, techniques – like anonymization – have only a small im-
pact on the computational complexity, but do not provide a high level
of security.
In the context of the project GeneCloud strategies are developed
to overcome issues in data security on identical complexity levels for
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Figure 22: As a first step,
data has to be encrypted
in a trusted environment.
Subsequently, the encrypted
data is transferred to an
untrusted environment e.g.
Cloud, where processing is
executed and encrypted re-
sults are obtained. After
transferring the encrypted re-
sults back to a trusted envi-
ronment, the data can be de-
crypted and the final results
accessed.
services in a potentially untrusted environment (public Cloud) [17].
The GeneCloud project aims to develop model services to enable se-
cure Cloud Computing in the drug development domain for small
and medium size enterprises, which allows the application of high
throughput methods in a secure manner.
Beck and co-workers present strategies – involving (homomorphic)
encryption, minimization and anonymization – that are tailored to
three case studies from different domains: Patent annotation (text
mining), cancer outcome prediction (translational bioinformatics), and
drug target prediction (structural bioinformatics) [18].
This chapter focuses on the results for the application of cancer
outcome prediction.
A fully data-centric security approach is presented, utilizing cus-
tomized algorithms to achieve a desired privacy-performance trade-
off. Figure 22 sketches the general idea of the GeneCloud project. In a
first step, sensible data is preprocessed and secured locally in full con-
trol of the user. Afterwards, the encrypted data is subsequently trans-
ferred to the potentially unsafe Cloud platform. Ideally, the Cloud
services run on the encrypted data, evading an access by an intruder
and ultimately decreasing privacy related usage restrictions of Cloud
infrastructure. After calculation, the encrypted result is transferred
back to the trusted environment, where it is decrypted for further
processing.
6.2 cancer outcome prediction
The main goal of outcome prediction lies in defining the future state
of a patient based on its current disease state. One method in cancer
outcome prediction is the analysis of gene expression with the help
of high-density oligonucleotide arrays. The gene signatures obtained
in such analyzes could be addressed as biomarkers for cancer pro-
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gression. In chapter 4 an algorithm – called NetRank – is described
that employs protein-protein interaction networks and ranks genes
by using the random surfer model of Google’s PageRank algorithm.
It has been shown, that NetRank improves the outcome prediction
accuracy compared to classical methods by 7% for pancreas cancer
patients [196] and provides an average 6% accuracy improvement on
a larger benchmark dataset, consisting of 13 different cancer types.
Analysis of NetRank
requirements
NetRank performs a supervised learning process combined with
a Monte Carlo cross-validation scheme to predict biomarker genes.
The main component of the algorithm is a matrix (network) – vector
(patient data) multiplication, thus having a computational complexity
of approximately O(N2). Depending on the amount of patients and
network size, the running time of one biomarker prediction can easily
reach up to 30.000 CPU h. In order to reduce this running time, each
cross-validation step is submitted to the Cloud as one worker process.
The gene expression data obtained from patients and some type of
interaction networks are highly confidential. Therefore, the security
of the input data and the predicted biomarkers should be guaranteed
in the Cloud environment. Extra computation time is needed de-
pending on applied security approach (e.g. blinding, homomorphic
encryption, and randomization) on the data.
NetRank is memory intensiveFor an efficient cross-validation the network and patient data is
loaded into memory, which introduces a memory-related overhead.
In the current version, running the matrix-vector multiplication with
a network of approximately 100.000 edges consumes at least 2 Giga-
byte of memory. For current network sizes, NetRank can be run on
commodity hardware having 4 GB RAM, but with increasing network
sizes this is growing up to terabytes, especially when testing several
networks at the same time, thus making the memory the major bot-
tleneck of the algorithm.
Since these factors cause the algorithm to be very memory inten-
sive, an optimization is necessary before efficiently running it on a
public Cloud.
6.3 security analysis
At the core of the NetRank algorithm are two important primitives,
matrix-vector multiplications and machine learning algorithms work-
ing on confidential data.
Privacy-preserving solutions for matrix-vector multiplications are
available based on different security assumptions like semi-honest
multi-party computation [10] or blinding [9, 11]. Solutions upon
blinding are implemented, which achieve a high efficiency, increased
privacy, but still leak some information.
Blinding as a fast security
approach
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Figure 23: For the random-
ization of vectors, the vector-
like patient data is trans-
formed in a trusted envi-
ronment by addition with a
random vector. Afterwards,
the matrix- vector multiplica-
tion is efficiently calculated in
the untrusted Cloud environ-
ment. The blinded result is
transferred back to the trusted
systems and decrypted via
subtraction by a prepared un-
blinding vector.
Figure 23 shows a schematic overview of the blinding process. For
data randomization the vector-like patient data is transformed in a
trusted environment by addition with a random vector. Afterwards,
the matrix-vector multiplication is efficiently calculated in the un-
trusted Cloud environment. The blinded result is transferred back
to the trusted systems and decrypted via subtraction by a prepared
un-blinding vector.
Homomorphic encryption is less
efficient but more secure
Another implemented solution is based on additive homomorphic
encryption [139]. The encrypted approach is perfectly preserving
privacy, but is less efficient than the blinding solution. It comes in
two possible flavors, using an additive encryption scheme to protect
one side of the matrix multiplication [139], or a scheme from pairing-
based cryptography that protects all input data with less efficiency
[24].
The machine learning part of NetRank was also targeted by specific
privacy-preserving solutions. Graepel et al. propose a new class of
machine learning algorithms based on leveled homomorphic encryp-
tion [99]. New binary classifiers are built with a multiplicative circuit
depth of low polynomial degree. This ensures rather efficient evalua-
tion through somewhat homomorphic encryption schemes. Another
efficient and less privacy-preserving solution based on blinding is
to randomize the data, while preserving important properties like
the order and approximate relative distance. The blinding based ap-
proach also yields comparable classification results on the original
data with nearly no performance impact. The achievable privacy mar-
gin is on the opposite rather low.
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6.4 conclusion
Due to the growing amount of biological data, applications in the bio-
medical sector have a rising demand for computational power. Often
the set-up of a whole computational infrastructure is too costly for
small companies or research institutes. Cloud computing might be
the solution to this problem. The cloud computing service provides
running of client software on a remote server location, hence provid-
ing distributed computing and shared services in a converged cloud
infrastructure. Unfortunately, data uploaded to the Cloud is often
confidential and need to be secured.
Cancer outcome prediction tries to forecast disease progression
from biological data (e.g. gene expression, sequencing etc.) and thus
allows refined treatment options. By using the secured Cloud en-
vironment, new biomarkers found by NetRank could be applied in
daily clinical routine and finally could suggest refined treatment op-
tions.
As the proposed security solution is independent of the actual
Cloud infrastructure, NetRank can be run on virtually any Cloud
platform.

7 C O N T R I B U T I O N S A N D
C O N C L U S I O N
This chapter highlights the solutions to the open problems listed in
chapter 1. It emphasizes the scientific contributions to analyze the
applicability of network information for cancer outcome prediction.
7.1 contributions
Open Question 1 : Does network information improve cancer
outcome prediction?
The goal is to show the general applicability of network-based pre-
diction methods that incorporate network information in gene ex-
pression analysis in cancer outcome prediction. The performance
should be assessed in comparison to standard outcome prediction
methods on a representative benchmark dataset.
In this work a network-based approach – NetRank – is used to show
the general applicability of network information in gene expression
analysis to improve the performance in cancer outcome prediction.
This analysis is conducted in chapter 4. For this purpose I created a
benchmark dataset consisting of 26 dataset covering a broad variety
of cancers and outcome variables. Before applying the algorithm on
the benchmark dataset, I analyzed the influence of several parameters
of NetRank e.g. the influence of the initial filtering, damping factor
and noise on the prediction results. Following, I compared the per-
formance of NetRank, classical methods and random predictors on
the benchmark dataset. Therefore, NetRank had to be adapted to run
on a cluster environment. Nevertheless, the evaluation of NetRank
on two networks took 60 CPU years for the calculation of 500 million
PageRanks.
This main analysis is followed by a secondary analysis regarding
general parameters influencing outcome prediction like cohort size
and outcome variable.
Finally, I conclude that network-based methods are especially suited
for biomarker discovery. These methods improve prediction accura-
cies across a variety of cancer types by selecting genes that are not
just correlating with but actively influencing the outcome of a patient.
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Open question 2: Is there a Universal Cancer signature?
The goal is to assess the similarity between predictive signatures
and how strongly published signatures are overlapping. Having
strongly overlapping signature between different cancer types, the
existence of a Universal Cancer Signature should be investigated
that is able to predict the outcome of a patient independent of
cancer type and outcome variable.
As the output of NetRank are highly overlapping signatures I inves-
tigated these similarities and compared them to signatures obtained
with classical methods and the original signatures from a benchmark
dataset consisting of 25 datasets. The results of this investigation are
shown in chapter 5. The strongly overlapping genes are analyzed re-
garding literature occurrence, connectivity and Hallmarks of cancer.
I analyze in detail six promising transcription factor and seven pro-
teins regarding their biological relevance to cancer development and
growth.
Subsequently, these genes are combined in different ways and sev-
eral tests are conducted to discover a Universal Cancer Signature.
No Universal Cancer Signature could be identified so far. Never-
theless a combination of general and cancer specific genes leads to
accurate prediction accuracies for a variety of cancers. Furthermore,
I created a pool of promising Universal Cancer genes, whose combi-
nation could reflect a common predictive signature.
7.2 open problem 1 revisited 105
7.2 open problem 1 revisited
In the last decade microarray studies developed to be a powerful tool
to predict outcome of patients in various diseases. Many recent micro-
array studies have been accepted by the Food and Drug Administra-
tion (FDA) and are nowadays included in clinical routines, allowing
personalized treatment options. Although the first diagnostic kits for
cancer outcome prediction are in the market, the criticism remains
that large signatures appear random, since other signatures perform
equally well.
Network information can help to improve outcome prediction and
reduce noise in microarray experiments. Many recent studies applied
network-based methods and successfully improved outcome predic-
tion of already published microarray data [40, 42, 45, 61, 129, 172, 181,
196].
Unfortunately, all these studies solely tested their approach on a
small amount of datasets, questioning the general applicability of
network-based methods for outcome prediction.
This is to my knowledge the first study to comprehensively test
a network-based approach on a variety of different gene expression
datasets. Our benchmark dataset is representative for all gene ex-
pression datasets as it covers 13 different cancer types, four distinct
outcome variables, a huge variety of cohort sizes, signature sizes and
statistical methodologies.
As representative of network-based methods, we adopted an algo-
rithm recently proposed – NetRank –, which is a PageRank derivative
working on gene-gene relationships. In this study NetRank employs
known transcription factor-target relationships and protein-protein
interactions for outcome prediction. For that purpose NetRank first
assigns a score for each gene and then the network is used to spread
this score to its neighbors and beyond. The genes with the highest
NetRank score are then selected as signature genes. Here, we fo-
cus on signatures that are compact, consisting of only 10 genes and,
therefore, can be easily tested in a clinical environment through inex-
pensive laboratory tests as RT-PCR or immunohistochemistry.
NetRank reliably predicts cancer
outcome
We found NetRank reliably predicting the outcome in the bench-
mark dataset with high prediction accuracies. Furthermore, there
was a consistent and significant improvement of the network-based
approach over random signatures and classical approaches based on
t-test or foldchange.
The purely computational
approach of NetRank approaches
the level of the authors’
signatures
We compared the NetRank accuracies with the accuracies found by
the original publications and showed that NetRank is approaching
the accuracy level of the authors’ signatures by applying a relatively
unbiased but fully automated process for biomarker discovery. Taken
together, a fully automated network-based approach – like NetRank –
is able to obtain similar results as the hand-selected signatures of the
106 contributions and conclusion
authors. In addition, also other network-based methods successfully
improved the prediction accuracy compared to the classical methods.
Regarding the open question, we conclude that NetRank is in par-
ticular suited for outcome prediction and that network-based meth-
ods in general improve prediction accuracies.
Signature size influences
prediction performance
Another question was the correlation of cohort and signature size
to prediction performance. On one hand we found a small correlation
of signature size with prediction accuracy, but on the other hand no
correlation for cohort size and accuracy could be observed.
Regulatory information best
suited for outcome prediction
An important open question is, which type of interaction is best
suited for outcome prediction. We experimented with a regulatory
(Transfac), physical interaction (HPRD) and two predicted networks
(hPrint, STRING). The latter are several orders of magnitude larger
than the first. Nonetheless, all can be considered as a fraction of the
complete interactome that is currently not yet known. Interestingly,
despite the size difference, they perform equally well. This leads to
the conclusion that regulatory information is particularly suited for
outcome prediction. Cancer often arises due to alterations in tran-
scription factor expression, leading to unregulated cell growth and
differentiation. Therefore, the efficiency of Transfac in cancer out-
come prediction is biologically reasonable. Transcription factors have
been already discussed as one of the main source of cancer devel-
opment [128] as well as suggested as targets for cancer therapy [47].
This implicates that future regulatory networks lead to further im-
provement in outcome prediction.
NetRank performance depends
on many parameters
We furthermore investigated several parameters influencing the re-
sult of NetRank, e.g. how the genes initial values or the damping
factor influences the results. The damping factor regulates the influ-
ence of the network on the results, as its balances the influence of
the expression and interaction on the results. A weak correlation of
d to accuracy improvement was observed, suggesting that increasing
coverage of the interactome may also lead to further improvements
in the prediction accuracy. The novelty of NetRank is the dynamical
setting of the damping factor during signature development. As each
dataset has its own dataset specific damping factor, the dynamical
setting has to be maintained for each new biomarker creation.
The genes initial value plays also an important role on the predic-
tion result. Initializing the genes with the same value instead with
the gene expression leads already to an improvement over classical
methods, but there is more prognostic information coming from the
concrete expression values.
During evaluation of all open questions, we made the following
discoveries regarding the outcome variable, the cancer bias and the
machine learning method.
Diagnosis is easier than
progression or treatment
While comparing the accuracies of the original publications, we
discovered that predicting response to treatment and progression are
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generally more difficult than diagnosis and subtyping. We hypothe-
sized that the former is more strongly influenced by external factors
such as age and sex. Furthermore, we conclude that in diagnosis
the gene expression signal is much stronger. This can be proven by
comparing the random accuracy of the prostate dataset in the bench-
mark dataset with any other accuracy obtained by more sophisticated
methods. The signal is strong enough to be captured even by random
gene selection.
No bias due to well-studied
proteins
Furthermore, we evaluated the disease bias that genes in the net-
works are often highly related to certain diseases. The results in-
dicate that the information gain achieved by NetRank is not solely
based on well-studied cancer proteins in networks but also on the in-
teraction between them. Whereas, limiting the search space to only
well-studied proteins for classical methods reduces the prediction per-
formance dramatically.
Choice of machine learning
method shows only small impact
on accuracy
Finally, we investigated the influence of several machine learning
approaches in outcome prediction. We could clearly observe a dif-
ference between diverse machine learning approaches. Overall, the
k-NN approach performs best. Nevertheless the differences are sub-
tle, thus the performance of the different machine learning methods
are comparable to each other.
Network-based outcome
prediction evaluation is
computational expensive
Due to the cross-validation step and the dynamical setting of the
damping factor included into NetRank, the calculation of a predictive
signature takes several thousand CPU h. The evaluation of the algo-
rithm on the whole benchmark dataset using two networks took 60
CPU years and the calculation of roughly 500 million PageRanks.
Regardless the quadratic running time, network-based gene expres-
sion analysis is leading to a more detailed understanding of cancer
and cancer-related processes by selecting highly relevant genes that
are not just correlating with but actively influencing the outcome of a
patient. Furthermore, putting prognostic signatures into the context
of pathways and network neighborhood may provide crucial infor-
mation to move from biomarkers to targets, whose modulation will
influence outcome.
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7.3 open problem 2 revisited
Cancer outcome prediction aims to forecast disease progression from
gene expression data. Is has been shown, that single gene markers
are not able to reliably predict cancer outcome. For that reason a
combination of several genes combined in a predictive signature is
nowadays used for outcome prediction. One success in this area is
the diagnostic assay MammaPrint R⃝, which predicts metastasis for-
mation in breast cancer based on the expression of 70 genes. Ein-Dor
and co-workers compared the breast cancer progression signature of
MammaPrint R⃝ with another study and found no significant signa-
ture overlap between these two gene sets. They furthermore claimed
that many equally predictive lists could have been produced [55].
When analyzing gene expression data with the purpose of finding
clinical relevant biomarkers for cancer outcome prediction, genes se-
lected for prediction should not just work on the initial dataset but
also on other patient data. Therefore, signatures created for the same
purpose should in general overlap. Having genes in common, these
genes should cover general signals in cancer development and ac-
cordingly overlap with the Hallmarks of cancer. These Hallmarks,
introduced by Hanahan and Weinberg in 2000, reduce cancer devel-
opment and growths to a small number of underlying principles [80].
No similarity between the
published signatures of the
benchmark dataset
First, we followed the hypothesis of Ein-Dor and co-workers and
compared the published signatures of the benchmark dataset regard-
ing their similarity. We could not find a significant similarity between
these signatures. Even for studies investigating the same cancer and
outcome variable, no overlapping genes exist, proving the point of
Ein-Dor et al..
No overlap between signatures
obtained by greedy methods
This lack of overlap might be due to different statistical method-
ologies employed during signature development. To investigate the
effect of the methods on the resulting predictive signatures, we ap-
plied two standard methods t-test and foldchange on all datasets. We
show that both techniques are not able to construct stable signatures
as no significant overlap between signatures was visible.
Network-based methods trigger
signatures similarity
Finally, we investigated whether network-based analysis of gene
expression data is able to improve the similarity between predictive
signatures. Thus, we analyzed the overlap of signatures obtained by
NetRank, which was applied on two types of networks – a protein-
protein interaction network (HPRD) and a transcription factor-target
network (Transfac). A statistically significant overlap of predictive
signatures was discovered and different datasets covering either the
same cancer type, as well as different cancer types overlap well. The
resulting signatures share 2 and 3.2 genes, respectively.
To summarize, NetRank, as a representative of network-based meth-
ods, is able to improve the similarity between signatures. The ques-
tion arises if this overlap is meaningful.
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Overlapping genes are biological
meaningful and cover
Hallmarks of cancer
To answer this question, the overlapping genes were investigated
regarding their occurrence in literature as cancer-related or cancer
biomarker. We found the overlapping genes are related to cancer and
have been mentioned already as biomarker for outcome prediction.
While examining the genes regarding the Hallmarks of cancer, we
show that the overlapping genes cover all Hallmarks and thus all
basic principles of cancer development. We in particular single out
six transcription factors and seven proteins and discuss their specific
role in cancer progression.
No Universal Cancer Signature
could be identified so far
Having this set of overlapping highly cancer-related genes, we con-
ducted several experiments to identify a Universal Cancer Signatures
that is able to predict cancer development and progression in a vari-
ety of different cancer types. So far no Universal Cancer Signature
could be identified. Nevertheless, we created a gene set consisting
out of 37 genes which are highly promiscuous as a member of a Uni-
versal Cancer Signature.
A combination of hub and
no-hub genes approximates
Universal Cancer Signature
We investigated the signatures regarding general and cancer spe-
cific genes and concluded that a combination of both achieves the
best result for all cancer types. Thus, the similarity between signa-
tures could be improved by using genes indicating general cancer
development and adding cancer specific genes.
Finally we compared our signatures to a signature published by
Bravo et al. which contains 715 unique genes and is able to distin-
guish healthy and cancer patients [27]. We show that our signatures
are partly overlapping with their anti-profile signature, indicating the
general applicability of general gene sets for outcome prediction.
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